WO2018136663A1 - Inhibiteurs de ret - Google Patents
Inhibiteurs de ret Download PDFInfo
- Publication number
- WO2018136663A1 WO2018136663A1 PCT/US2018/014281 US2018014281W WO2018136663A1 WO 2018136663 A1 WO2018136663 A1 WO 2018136663A1 US 2018014281 W US2018014281 W US 2018014281W WO 2018136663 A1 WO2018136663 A1 WO 2018136663A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound according
- ret
- alkyl
- optionally substituted
- methyl
- Prior art date
Links
- 0 CC(C1)C([C@](*=C(C)C=C(C)C)N)=C=*C/C=C1/*(CCC(C1)*CCC=C*CC#CC1=C)=C Chemical compound CC(C1)C([C@](*=C(C)C=C(C)C)N)=C=*C/C=C1/*(CCC(C1)*CCC=C*CC#CC1=C)=C 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present disclosure relates to novel compounds which exhibit Rearranged during Transfection (RET) kinase inhibition, pharmaceutical compositions comprising the compounds, processes for making the compounds, and the use of the compounds in therapy. More particularly, it relates to substituted 2-(pyridin-3-yl)-pyrimidine compounds useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
- RET Rearranged during Transfection
- RET is a single-pass transmembrane receptor belonging to the tyrosine kinase superfamily that is required for normal development, maturation, and maintenance of several tissues and cell types (Mulligan, L. M., Nature Reviews Cancer, 2014, 14, 173-186).
- the extracellular portion of the RET kinase contains four calcium-dependent cadherin-like repeats involved in ligand binding and a juxtamembrane cysteine-rich region necessary for the correct folding of the RET extracellular domain, while the cytoplasmic portion of the receptor includes two tyrosine kinase subdomains.
- RET signaling is mediated by the binding of a group of soluble proteins of the glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs), which also includes neurturin (NTRN), artemin (ARTN) and persephin (PSPN) (Arighi et al., Cytokine Growth Factor Rev., 2005, 16, 441-67).
- GDNF glial cell line-derived neurotrophic factor
- NTRN neurturin
- ARTN artemin
- PSPN persephin
- RET does not directly bind to GFLs and requires an additional co-receptor: that is, one of four GDNF receptor-a (GFRa) family members, which are tethered to the cell surface by a glycosylphosphatidylinositol linkage.
- GFLs and GFRa family members form binary complexes that in turn bind to RET and recruit it into cholesterol- rich membrane subdomains, which
- RET dimerization and autophosphorylation on intracellular tyrosine residues recruits adaptor and signaling proteins to stimulate multiple downstream pathways.
- Adaptor protein binding to these docking sites leads to activation of Ras-MAPK and PBK-Akt/mTOR signaling pathways or to recruitment of the CBL family of ubiquitin ligases that functions in RET downregulation of the RET-mediated functions.
- composition comprising a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, in admixture with a pharmaceutically acceptable diluent or carrier.
- Also provided herein is a method of inhibiting cell proliferation, in vitro or in vivo, the method comprising contacting a cell with an effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof as defined herein.
- Also provided herein is a method of treating a RET-associated disease or disorder in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof as defined herein.
- Also provided herein is a method of treating cancer and/or inhibiting metastasis associated with a particular cancer in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof as defined herein.
- Also provided herein is a method of treating irritable bowel syndrome (IBS) and/or pain associated with IBS in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof as defined herein.
- IBS irritable bowel syndrome
- Also provided herein is a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof as defined herein for use in therapy.
- Also provided herein is a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof as defined herein for use in the treatment of cancer and/or inhibiting metastasis associated with a particular cancer.
- IBS irritable bowel syndrome
- a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof as defined herein for use providing supportive care to a cancer patient, including preventing or minimizing gastrointestinal disorders, such as diarrhea, associated with treatment, including chemotherapeutic treatment.
- Also provided herein is a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof for use in the inhibition of RET kinase activity.
- Also provided herein is a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof as defined herein, for use in the treatment of a RET-associated disease or disorder.
- a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof as defined herein in the manufacture of a medicament for the treatment of cancer and/or inhibiting metastasis associated with a particular cancer.
- a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof as defined herein in the manufacture of a medicament for the treatment of irritable bowel syndrome (IBS) or pain associated with IBS.
- IBS irritable bowel syndrome
- a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof as defined herein in the manufacture of a medicament for providing supportive care to a cancer patient, including preventing or minimizing gastrointestinal disorders, such as diarrhea, associated with treatment, including chemotherapeutic treatment.
- Also provided herein is a use of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, as defined herein in the manufacture of a medicament for the inhibition of RET kinase activity.
- Also provided herein is the use of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, as defined herein, in the manufacture of a medicament for the treatment of a RET-associated disease or disorder.
- a pharmaceutical combination for treating cancer e.g., a
- RET-associated cancer such as a RET-associated cancer having one or more RET inhibitor resistance mutations
- a patient in need thereof which comprises (a) a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, (b) an additional therapeutic agent, and (c) optionally at least one pharmaceutically acceptable carrier, wherein the compound of Formula I or the pharmaceutically acceptable salt or solvate thereof and the additional therapeutic are formulated as separate compositions or dosages for simultaneous, separate or sequential use for the treatment of cancer, wherein the amounts of the compound of Formula I or a pharmaceutically acceptable salt or solvate thereof and of the additional therapeutic agent are together effective in treating the cancer.
- a pharmaceutical composition comprising such a combination.
- Also provided herein is a method for reversing or preventing acquired resistance to an anticancer drug, comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, to a patient at risk for developing or having acquired resistance to an anticancer drug.
- the patient is administered a dose of the anticancer drug (e.g., at substantially the same time as a dose of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof is administered to the patient).
- Also provided herein is a method of delaying and/or preventing development of cancer resistant to an anticancer drug in an individual, comprising administering to the individual an effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, before, during, or after administration of an effective amount of the anticancer drug.
- Also provided herein is a method of treating an individual with cancer who has an increased likelihood of developing resistance to an anticancer drug, comprising administering to the individual (a) an effective amount of a compound of Formula I before, during, or after administration of (b) an effective amount of the anticancer drug.
- Also provided are methods of treating an individual with a RET-associated cancer that has one or more RET inhibitor resistance mutations that increase resistance of the cancer to a first RET inhibitor e.g., one or more amino acid substitutions in the kinase domain (e.g., amino acid positions 723 to 1012 in a wildtype RET protein), a gatekeeper amino acid (e.g., amino acid position 804 in a wildtype RET protein), the P-loop (e.g., amino acid positions 730-737 in a wildtype RET protein), the DFG motif (e.g., amino acid positions 892-894 in a wildtype RET protein), ATP cleft solvent front amino acids (e.g., amino acid positions 758, 811, and 892 in a wildtype RET protein), the activation loop (e.g., amino acid positions 891-916 in a wildtype RET protein), the C-helix and loop preceeding the C-helix (e.g., amino acid positions 7
- a wildtype RET protein is the exemplary wildtype RET protein described herein.
- Also provided are methods of treating an individual with a RET-associated cancer that include administering a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, before, during, or after administration of another anticancer drug (e.g., a first RET kinase inhibitor).
- a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof before, during, or after administration of another anticancer drug (e.g., a first RET kinase inhibitor).
- a method for treating irritable bowel syndrome (IBS) in a patient in need thereof comprising (a) determining if the IBS is associated with a dysregulation of a RET gene, a RET kinase, or expression or activity or level of any of the same; and (b) if the IBS is determined to be associated with a dysregulation of a RET gene, a RET kinase, or expression or activity or level of any of the same, administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof.
- IBS irritable bowel syndrome
- a pharmaceutical combination for treating irritable bowel syndrome which comprises administering (a) a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, (b) an additional therapeutic agent, and (c) optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use for the treatment of IBS, wherein the amounts of the compound of Formula I or a pharmaceutically acceptable salt or solvate thereof and of the additional therapeutic agent are together effective in treating the IBS.
- a pharmaceutical composition comprising such a combination. Also provided herein is the use of such a combination for the preparation of a medicament for the treatment of the IBS.
- a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of the IBS a patient in need thereof.
- all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
- A is selected from:
- R a is H or C 1 -C6 alkyl
- Ar 1 is phenyl optionally substituted with one or more substituents independently selected from the group consisting of H, halogen, OH, CN, C1-C6 alkyl- (optionally substituted with 1-3 fluoros), hydroxyCl-C6 alkyl- (optionally substituted with 1-3 fluoros), C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R k RTNT-, wherein R b and R c are independently H or Cl-C6 alkyl,
- hetAr 2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein hetAr 2 is optionally substituted with one or more substituents independently selected from the group consisting of H, halogen, OH, CN, C1-C6 alkyl- (optionally substituted with 1-3 fluoros), C3-C6 cycloalkyl-, hydroxyCl-C6 alkyl- (optionally substituted with 1-3 fluoros), C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R ⁇ 'TST-, wherein R b and R c are independently H or C1-C6 alkyl,
- hetCyc 1 is a 4-6 membered saturated heterocyclic ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein the heterocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of H, halogen, OH, CN, C1-C6 alkyl- (optionally substituted with 1-3 fluoros), hydroxyCl-C6 alkyl- (optionally substituted with 1-3 fluoros), C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R b R c N-, wherein R b and R c are independently H or C1-C6 alkyl;
- B is selected from:
- R a is H or C 1 -C6 alkyl
- Ar 3 is phenyl optionally substituted with one or more substituents independently selected from the group consisting of H, halogen, OH, CN, C1-C6 alkyl- (optionally substituted with 1-3 fluoros), hydroxyCl-C6 alkyl- (optionally substituted with 1-3 fluoros), C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R b R c N-, wherein R b and R c are independently H or Cl-C6 alkyl,
- hetAr 4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein hetAr 2 is optionally substituted with one or more substituents independently selected from the group consisting of H, halogen, OH, CN, C1-C6 alkyl- (optionally substituted with 1-3 fluoros), C3-C6 cycloalkyl-, hydroxyCl-C6 alkyl- (optionally substituted with 1-3 fluoros), C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R ⁇ 'TST-, wherein R b and R c are independently H or C1-C6 alkyl,
- hetCyc 2 is a 4-6 membered saturated heterocyclic ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein the heterocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of H, halogen, OH, CN, C1-C6 alkyl- (optionally substituted with 1-3 fluoros), hydroxyCl-C6 alkyl- (optionally substituted with 1-3 fluoros), C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R b R c N-, wherein R b and R c are independently H or C1-C6 alkyl;
- X 1 , X 2 , X 3 and X 4 are independently CH, CF or N, wherein 0, 1 or 2 of X 1 , X 2 , X 3 and X 4 is N;
- Y is a bond, - R d -, - R d (Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), or -(C1-C6 alkyl) R d - (optionally substituted with 1-3 fluoros), wherein R d is H or C1-C3 alkyl (optionally substituted with 1-3 fluoros);
- R 1 and R 2 at each occurrence are independently selected from the group consisting of halogen, OH, C1-C6 alkyl- (optionally substituted with 1-3 fluoros), hydroxyC2-C6 alkyl- (wherein the alkyl portion is optionally substituted with 1-3 fluoros), dihydroxyC3-C6 alkyl-, (Cl- C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (R ⁇ Cl-Ce alkyl-, wherein R e and R f are independently H or C1-C6 alkyl (optionally substituted with 1-3 fluoros), and (C3- C6 cycloalkyl)Cl-C3 alkyl-;
- n 0, 1 or 2;
- m is 0, 1 or 2.
- A is selected from:
- Ar 1 is phenyl optionally substituted with one or more substituents independently selected from the group consisting of CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros), and oxo, and
- hetAr 2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein hetAr 2 is optionally substituted with one or more substituents independently selected from the group consisting of CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros), and oxo;
- B is selected from:
- Ar 3 is phenyl optionally substituted with one or more substituents independently selected from the group consisting of H, halogen, C1-C6 alkyl (optionally substituted with 1-3 fluoros), and C1-C6 alkoxy (optionally substituted with 1-3 fluoros), and
- hetAr 4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein hetAr 2 is optionally substituted with one or more substituents independently selected from the group consisting of H, halogen, C1-C6 alkyl (optionally substituted with 1-3 fluoros), and C3-C6 cycloalkyl;
- X 1 , X 2 , X 3 and X 4 are independently CH, CF or N, wherein 0, 1 or 2 of X 1 , X 2 , X 3 and X 4 is N;
- Y is - R d - or - R d (C 1 -C6 alkyl)- (optionally substituted with 1 -3 fluoros), wherein
- R d is H or C1-C3 alkyl (optionally substituted with 1-3 fluoros);
- R 1 and R 2 at each occurrence are independently selected from the group consisting of H, halogen, and C1-C6 alkyl- (optionally substituted with 1-3 fluoros);
- n 1 or 2;
- m is 1 or 2.
- A is Ar 1 , where Ar 1 is phenyl optionally substituted with one or more substituents independently selected from the group consisting of H, or CN. In certain embodiments of Formula I, A is Ar 1 , where Ar 1 is phenyl substituted with CN.
- A is hetAr 2 , where hetAr 2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein hetAr 2 is optionally substituted with one or more substituents independently selected from the group consisting of H, CN, C1-C6 alkyl, hydroxyCl-C6 alkyl, and oxo.
- hetAr 2 is a 5 membered heteroaryl ring having 2 heteroatoms independently selected from N, O, and S.
- hetAr 2 is a 5 membered heteroaryl ring having 3 heteroatoms independently selected from N, O, and S. In certain embodiments, hetAr 2 is a 6 membered heteroaryl ring having 1 heteroatom that is N. In certain embodiments, hetAr 2 is 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from N, O and S, wherein hetAr 2 is substituted with CN. In certain embodiments, hetAr 2 is 5-6 membered heteroaryl ring having 1- 3 heteroatoms independently selected from N, O and S, wherein hetAr 2 is substituted with oxo.
- hetAr 2 is a 6 membered heteroaryl ring having 1 heteroatom that is N, wherein hetAr 2 is substituted with C1-C6 alkyl and oxo. In certain embodiments, hetAr 2 is 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from N, O and S, wherein hetAr 2 is substituted with C1-C3 alkyl. In certain embodiments, hetAr 2 is 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from N, O and S, wherein hetAr 2 is substituted with h droxyCl-C3 alkyl.
- Non-limiting examples of hetAr 2 include the structures:
- B is Ar , where Ar is phenyl optionally substituted with one or more substituents independently selected from the group consisting of H, halogen, C1-C6 alkyl, and C1-C6 alkoxy.
- B is Ar 3 , where Ar 3 is phenyl substituted with H.
- B is Ar 3 , where Ar 3 is phenyl substituted with halogen.
- B is Ar 3 , where Ar 3 is phenyl substituted with F.
- B is Ar 3 , where Ar 3 is phenyl substituted with C1-C6 alkyl.
- B is Ar 3 , where Ar 3 is phenyl substituted with C1-C6 alkoxy. In certain embodiments of Formula I, B is Ar 3 , where Ar 3 is phenyl substituted with methoxy. In certain embodiments of Formula I, B is Ar 3 , where Ar 3 is phenyl substituted with methyl and F.
- B is hetAr 4 , where hetAr 4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein hetAr 4 is optionally substituted with one or more substituents independently selected from the group consisting of H, halogen, C1-C6 alkyl, and C3-C6 cycloalkyl.
- hetAr 4 is a 5 membered heteroaryl ring having 2 ring heteroatoms that are both N.
- hetAr 4 is a 5 membered heteroaryl ring having 2 ring heteroatoms that are both N, wherein hetAr 4 is substituted with halogen. In certain embodiments, hetAr 4 is a 5 membered heteroaryl ring having 2 ring heteroatoms that are both N, wherein hetAr 4 is substituted with F. In certain embodiments, hetAr 4 is a 5 membered heteroaryl ring having 2 ring heteroatoms that are both N, wherein hetAr 4 is substituted with C1-C3 alkyl.
- hetAr 4 is a 5 membered heteroaryl ring having 2 ring heteroatoms that are both N, wherein hetAr 4 is substituted with 1-2 methyls. In certain embodiments, hetAr 4 is a 5 membered heteroaryl ring having 2 ring heteroatoms that are both N, wherein hetAr 4 is substituted with C3-C6 cycloalkyl. In certain embodiments, hetAr 4 is a 5 membered heteroaryl ring having 2 ring heteroatoms that are both N, wherein hetAr 4 is substituted with cyclopropyl.
- hetAr 4 is a 6 membered heteroaryl having 1 ring heteroatom that is N. In certain embodiments, hetAr 4 is a 6 membered heteroaryl having 1 ring heteroatom that is N, wherein hetAr 4 is substituted with C1-C6 alkoxy. In certain embodiments, hetAr 4 is a 6 membered heteroaryl having 1 ring heteroatom that is N, wherein hetAr 4 is substituted with C1-C6 alkyl. In certain embodiments, hetAr 4 is a 6 membered heteroaryl having 1 ring heteroatom that is N, wherein hetAr 4 is substituted with halogen. In certain embodiments, hetAr 4 is a 6 membered heteroaryl having 1 ring heteroatom that is N, wherein ctures:
- X 1 , X 2 , X 3 and X 4 are independently CH or
- each of X 1 , X 2 , X 3 and X 4 is CH.
- X 1 , X 2 , X 3 and X 4 are independently CH or
- X 1 , X 2 , X 3 and X 4 are N and the remainder are CH.
- X 3 is N
- X 1 , X 2 and X 4 are CH.
- X 1 , X 2 , X 3 and X 4 are independently CH or
- X 1 , X 2 , X 3 and X 4 are N.
- X 1 and X 3 are N and X 2 and X 4 are CH.
- Y is -NR d (Cl-C6 alkyl)-, wherein R d is H or
- C1-C3 alkyl examples include methyl, ethyl, propyl, and isopropyl.
- R 1 at each occurrence is independently Cl-
- R 1 is C1-C3 alkyl. In certain embodiments of Formula I, R 1 is methyl.
- R 2 at each occurrence is independently selected from the group consisting of H, halogen, and C1-C6 alkyl.
- R 2 is H.
- R 2 is halogen.
- R 2 is F.
- R 2 is C1-C6 alkyl.
- R 2 is methyl.
- the compound of Formula I is a compound of Formula la
- B is selected from Ar 3 or hetAr 4 ,
- Ar 3 is phenyl optionally substituted with one or more substituents independently selected from the group consisting of H, halogen, OH, CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros), C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R k RTNT-, wherein R b and R c are independently H or Cl-C6 alkyl,
- hetAr 4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein hetAr 2 is optionally substituted with one or more substituents independently selected from the group consisting of H, halogen, OH, CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), C3-C6 cycloalkyl, hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros, C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R b R c N-, wherein R b and R c are independently H or C1-C6 alkyl;
- X 1 , X 2 , and X 4 are each CH and X 3 is N, or X 2 and X 4 are each CH and X 1 and X 3 are each N;
- Y is -NR d (Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), wherein R d is H or C1-C3 alkyl (optionally substituted with 1-3 fluoros);
- Z 1 , Z 2 and Z 3 are each independently selected from CH, N, NH, O or S;
- R 1 is C1-C6 alkyl-
- R 2 is selected from the group consisting of H, halogen, or C1-C6 alkyl- (optionally substituted with 1-3 fluoros);
- R 3 is selected from the group consisting of CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), and hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros); and [00125] m is l .
- B is Ar 3 .
- B is hetAr 4 , substituted with one or more substituents independently selected from the group consisting of halogen, alkoxyCl-C3 alkyl, C3- C6 cycloalkyl, and C1-C3 alkyl.
- X 1 , X 2 , and X 4 are each CH and X 3 is N.
- X 2 and X 4 are each CH and X 1 and X 3 are each N.
- Y is - R d (Cl-C6 alkyl)-, wherein R d is methyl.
- Y is - R d (Cl-C6 alkyl)-, wherein R d is H.
- Y is - HCH2-.
- Y is - HCH(CH3)-.
- R 1 is C1-C3 alkyl.
- R 1 is methyl
- R 2 is halogen
- R 2 is F.
- R 2 is C1-C3 alkyl.
- R 2 is methyl
- R 3 is CN
- R 3 is hydroxyCl-C6 alkyl.
- R 3 is C1-C3 alkyl.
- R 3 is methyl
- R 3 is ethyl
- Z 1 is N or NH.
- Z 1 is CH.
- Z 2 is N or NH.
- Z 2 is O.
- Z 2 is S.
- Z 3 is CH.
- Z 3 is N or NH.
- Z 1 is NH
- Z 2 is N
- Z 3 is CH.
- Z 1 is N
- Z 2 is O
- Z 3 is CH
- Z 1 is N
- Z 2 is O
- Z 3 is N
- Z 1 is N
- Z 2 is S
- Z 3 is CH
- Z 1 is N
- Z 2 is S
- Z 3 is N
- Z 1 is CH
- Z 2 is NH
- Z 3 is N.
- Z 1 is N
- Z 2 is NH
- Z 3 is CH.
- R 1 is methyl
- R 3 is CN
- Z 1 is NH
- Z 2 is N
- Z 3 is CH.
- R 1 is methyl
- R 3 is CN
- Z 1 is N
- Z 2 is O
- Z 3 is CH.
- R 1 is methyl
- R 3 is CN
- Z 1 is N
- Z 2 is O
- Z 3 is N.
- R 1 is methyl
- R 3 is CN
- Z 1 is N
- Z 2 is S
- Z 3 is CH.
- R 1 is methyl
- R 3 is CN
- Z 1 is N
- Z 2 is S
- Z 3 is N.
- R 1 is methyl
- R 3 is CN
- Z 1 is CH
- Z 2 is NH
- Z 3 is N.
- R 1 is methyl
- R 3 is CN
- Z 1 is N
- Z 2 is NH
- Z 3 is CH.
- R 1 is methyl
- R 3 is hydroxyCl-C6 alkyl
- Z 1 is N
- Z 2 is NH
- Z 3 is CH.
- R 1 is methyl
- R 3 is C1-C3 alkyl
- Z 1 is N
- Z 2 is NH
- Z 3 is CH.
- the compound of Formula I is a compound of Formula lb
- [00170] B is selected from Ar 3 or hetAr 4 ,
- Ar 2 is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, OH, CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros), C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R b R c N-, wherein R b and R c are independently H or Cl-C6 alkyl,
- hetAr 4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein hetAr 2 is optionally substituted with one or more substituents independently selected from the group consisting of halogen, OH, CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), C3-C6 cycloalkyl, hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros, C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R b R c N-, wherein R b and R c are independently H or C1-C6 alkyl;
- X 1 , X 2 , and X 4 are each CH and X 3 is N, or X 2 and X 4 are each CH and X 1 and X 3 are each N;
- Y is -NR d (Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), wherein R d is H or C1-C3 alkyl (optionally substituted with 1-3 fluoros);
- Z 4 is CH or N
- R 1 is C1-C6 alkyl-
- R 2 is selected from the group consisting of H, halogen, or C1-C6 alkyl- (optionally substituted with 1-3 fluoros);
- R 4 is CN
- m is l .
- B is Ar 3 .
- B is hetAr 4 , substituted with one or more substituents independently selected from the group consisting of halogen, alkoxyCl-C3 alkyl, C3- C6 cycloalkyl, and C1-C3 alkyl.
- n some embodiments of Formula lb, X 1 , X 2 , and X 4 are each CH and X 3 is N.
- n some embodiments of Formula lb, X 2 and X 4 are each CH and X 1 and X 3 are each N.
- Y is - R d (Cl-C6 alkyl)-, wherein R d is methyl.
- the compound of Formula I is a compound of Formula Ic
- Ar 3 is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, OH, CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros), C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R b R c N-, wherein R b and R c are independently H or Cl-C6 alkyl,
- hetAr 4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein hetAr 2 is optionally substituted with one or more substituents independently selected from the group consisting of halogen, OH, CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), C3-C6 cycloalkyl, hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros, C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R b R c N-, wherein R b and R c are independently H or C1-C6 alkyl;
- X 1 , X 2 , and X 4 are each CH and X 3 is N, or X 2 and X 4 are each CH and X 1 and X 3 are each N;
- Y is -NR d (C 1 -C6 alkyl)- (optionally substituted with 1 -3 fluoros), wherein R d is H or C1-C3 alkyl (optionally substituted with 1-3 fluoros);
- R 1 is C1-C6 alkyl-
- R 2 is selected from the group consisting of H, halogen, or C1-C6 alkyl- (optionally substituted with 1-3 fluoros);
- R 5 is H or C 1 -C6 alkyl-
- m is l .
- B is Ar 3 .
- B is hetAr 4 , substituted with one or more substituents independently selected from the group consisting of halogen, alkoxyCl-C3 alkyl, C3- C6 cycloalkyl, and C1-C3 alkyl.
- X 1 , X 2 , and X 4 are each CH and X 3 is N.
- X 2 and X 4 are each CH and X 1 and X 3 are each N.
- Y is -NR d (Cl-C6 alkyl)-, wherein R d is methyl.
- Y is -NR d (Cl-C6 alkyl)-, wherein R d is H.
- R d is H.
- Y is - HCH2-.
- Y is - HCH(CH3)-.
- R 1 is C1-C3 alkyl-.
- R 1 is methyl
- R 2 is halogen
- R 2 is F.
- R 2 is C1-C3 alkyl.
- R 2 is methyl
- R 5 is H.
- R 5 is C1-C6 alkyl-.
- R 5 is methyl
- R 1 is methyl and R 5 is H.
- R 1 is methyl and R 5 is methyl.
- the compound of Formula I is a compound of Formula Id
- A is selected from Ar 1 or hetAr 2 ,
- Ar 1 is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, OH, CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros), C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R b R c N-, wherein R b and R c are independently H or Cl-C6 alkyl,
- hetAr 2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein hetAr 2 is optionally substituted with one or more substituents independently selected from the group consisting of halogen, OH, CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), C3-C6 cycloalkyl, hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros, C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R k RTNT-, wherein R b and R c are independently H or C1-C6 alkyl;
- X 2 is CH or N
- R 1 is C1-C6 alkyl-
- R 2 is selected from the group consisting of H, halogen, or C1-C6 alkyl- (optionally substituted with 1-3 fluoros);
- R 6 is H or Cl-C6 alkyl
- R 7 , R 8 , and R 9 are each independently selected from the group consisting of H, halogen, C1-C6 alkyl-, and C3-C6 cycloalkyl;
- n is i .
- A is Ar 1 , substituted with CN.
- A is hetAr 2 , substituted with one or more substituents independently selected from the group consisting of CN, oxo, hydroxyCl-C3 alkyl, and C1-C3 alkyl.
- X 2 is CH.
- X 2 is N.
- R 1 is methyl
- R 2 is H.
- R 2 is halogen
- R 2 is F.
- R 2 is C1-C6 alkyl
- R 2 is Cl-C3 alkyl
- R 2 is methyl
- R 6 is H.
- R 6 is C1-C6 alkyl
- R 6 is Cl-C3 alkyl
- R 6 is methyl
- R 7 is H.
- R 7 is C1-C6 alkyl
- R 7 is Cl-C3 alkyl
- R 7 is methyl.
- R 8 is H.
- R 8 is halogen
- R 8 is F.
- R 8 is C1-C6 alkyl.
- R 8 is C1-C3 alkyl.
- R 8 is methyl
- R 9 is H.
- R 9 is C1-C6 alkyl.
- R 9 is C1-C3 alkyl.
- R 9 is methyl
- R 9 is C3-C6 cycloalkyl.
- R 9 is cyclopropane.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R is H
- R 8 is H
- R 9 is H
- X 2 is CH.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R is H
- R 8 is H
- R 9 is H
- X 2 is N.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R is H
- R 8 is F
- R 9 is H
- X 2 is CH.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R is H
- R 8 is F
- R 9 is H
- X 2 is N.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R is H
- R 8 is methyl
- R 9 is H
- X 2 is CH.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R is H
- R 8 is methyl
- R 9 is H
- X 2 is N.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R is methyl
- R 8 is H
- R 9 is methyl
- X 2 is CH.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R is methyl
- R 8 is H
- R 9 is methyl
- X 2 is N.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R is H
- R 8 is H
- R 9 is cyclopropyl
- X 2 is CH.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R is H
- R 8 is H
- R 9 is cyclopropyl
- X 2 is N.
- the compound of Formula I is a compound of Formula le
- A is selected from Ar 1 or hetAr 2 ,
- Ar 1 is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, OH, CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros), C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R b R c N-, wherein R b and R c are independently H or Cl-C6 alkyl,
- hetAr 2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein hetAr 2 is optionally substituted with one or more substituents independently selected from the group consisting of halogen, OH, CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), C3-C6 cycloalkyl, hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros, C1-C6 alkoxy (optionally substituted with 1-3 fluoros), oxo, and R b R c N-, wherein R b and R c are independently H or C1-C6 alkyl;
- X 2 is CH or N
- R 1 is C1-C6 alkyl-
- R 2 is selected from the group consisting of H, halogen, or C1-C6 alkyl- (optionally substituted with 1-3 fluoros);
- R 6 is H or Cl-C6 alkyl
- R 10 at each occurrence is independently selected from the group consisting of halogen, C1-C6 alkyl-, and C1-C6 alkoxy;
- n is i ;
- p is 1 or 2.
- X 2 is CH.
- X 2 is N.
- A is Ar 1 , substituted with CN.
- A is hetAr 2 , substituted with one or more substituents independently selected from the group consisting of CN, oxo, hydroxyCl-C3 alkyl, and C1-C3 alkyl.
- R 1 is methyl
- R 2 is H.
- R 2 is halogen
- R 2 is F.
- R 2 is C1-C6 alkyl.
- R 2 is C1-C3 alkyl.
- R 2 is methyl
- R 6 is H.
- R 6 is C1-C6 alkyl.
- R 6 is C1-C3 alkyl.
- R 6 is methyl
- R 10 is halogen
- R 10 is F.
- R 10 is C1-C6 alkyl.
- R 10 is Cl-C3 alkyl.
- R 10 is methyl
- R 10 is Cl-C6 alkoxy.
- R 10 is Cl-C3 alkoxy.
- R 10 is methoxy
- p is 1.
- p is 2.
- p is 2 and R 10 is F and methyl.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R 10 is methoxy
- X 2 is CH
- p is 1.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R 10 is methoxy
- X 2 is N
- p is 1.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R is methyl and F
- X 2 is CH
- p is 2.
- R 2 is H, F, or methyl
- R 6 is H or methyl
- R is methyl and F
- X 2 is N
- p is 2.
- the compound of Formula I is a compound of Formula If
- X 2 is CH or N
- Z 1 , Z 2 and Z 3 are each independently selected from CH, N, NH, O or S;
- R 1 is C1-C6 alkyl-
- R 2 is selected from the group consisting of H, halogen, or C1-C6 alkyl- (optionally substituted with 1-3 fluoros);
- R 3 is selected from the group consisting of CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), and hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros); and
- R 6 is H or Cl-C6 alkyl
- R 7 , R 8 , and R 9 are each independently selected from the group consisting of H, halogen, C1-C6 alkyl-, and C3-C6 cycloalkyl.
- X 2 is CH.
- z 1 is N or NH.
- z 1 is CH.
- z 2 is N or NH.
- z 2 is S.
- z 3 is CH.
- z 3 is N or H.
- R 1 is C1-C3 alkyl.
- R 1 is methyl
- R 3 is CN
- R 3 is hydroxyCl-C6 alkyl.
- R 3 is C1-C3 alkyl.
- R 3 is methyl
- R 3 is ethyl
- R 6 is H.
- R 6 is C1-C6 alkyl.
- R 6 is C1-C3 alkyl.
- R 6 is methyl
- R 7 is H.
- R 7 is C1-C6 alkyl.
- R 7 is C1-C3 alkyl.
- R 7 is methyl
- R 8 is H.
- R 8 is halogen
- R 8 is F.
- R 8 is C1-C6 alkyl.
- R 8 is C1-C3 alkyl.
- R 8 is methyl
- R 9 is H.
- R 9 is C1-C6 alkyl.
- R 9 is C1-C3 alkyl.
- R 9 is methyl
- R 9 is C3-C6 cycloalkyl.
- R 9 is cyclopropane.
- the compound of Formula I is a compound of Formula Ig
- X 2 is CH or N
- Z 1 , Z 2 and Z 3 are each independently selected from CH, N, NH, O or S;
- R 1 is C1-C6 alkyl-
- R 2 is selected from the group consisting of H, halogen, or C1-C6 alkyl- (optionally substituted with 1-3 fluoros);
- R 3 is selected from the group consisting of CN, C1-C6 alkyl (optionally substituted with 1-3 fluoros), and hydroxyCl-C6 alkyl (optionally substituted with 1-3 fluoros);
- R 6 is H or Cl-C6 alkyl
- R 10 at each occurrence is independently selected from the group consisting of halogen, C1-C6 alkyl-, and C1-C6 alkoxy;
- p is 1 or 2.
- X 2 is CH.
- X 2 is N.
- Z 1 is N or NH.
- Z 1 is CH.
- Z 2 is N or NH.
- Z 2 is O.
- Z 2 is S.
- Z 3 is CH.
- Z 3 is N or H.
- Z 1 is H
- Z 2 is N
- Z 3 is CH
- Z 1 is N
- Z 2 is O
- Z 3 is CH
- Z 1 is N
- Z 2 is O
- Z 3 is N
- Z 1 is N
- Z 2 is S
- Z 3 is CH
- Z 1 is N
- Z 2 is S
- Z 3 is N
- Z 1 is CH
- Z 2 is NH
- Z 3 is N.
- Z 1 is N
- Z 2 is NH
- Z 3 is CH.
- R 1 is methyl
- R 3 is CN
- R 3 is hydroxyCl-C6 alkyl.
- R 3 is Cl-C3 alkyl.
- R 3 is methyl
- R 3 is ethyl
- R 6 is H.
- R 6 is C1-C6 alkyl.
- R 6 is Cl-C3 alkyl.
- R 6 is methyl
- R 10 is halogen
- R 10 is F.
- R 10 is C1-C6 alkyl.
- R 10 is Cl-C3 alkyl.
- R 10 is methyl
- R 10 is Cl-C6 alkoxy.
- R 10 is Cl-C3 alkoxy.
- R 10 is methoxy
- p is 2 and R 10 is F and methyl.
- the compound of Formula I is a compound of Formula Ih
- X 2 is CH or N
- Z 4 is CH or N
- R 1 is C1-C6 alkyl-
- R 2 is selected from the group consisting of H, halogen, or C1-C6 alkyl- (optionally substituted with 1-3 fluoros);
- R 4 is CN
- R 6 is H or C1-C6 alkyl
- R 7 , R 8 , and R 9 are each independently selected from the group consisting of H, halogen, C1-C6 alkyl-, and C3-C6 cycloalkyl.
- R 1 is Cl-C3 alkyl
- R 1 is methyl
- R 4 is CN
- R 6 is H.
- R 6 is C1-C6 alkyl
- R 6 is Cl-C3 alkyl
- R 6 is methyl
- R 7 is H.
- R 7 is C1-C6 alkyl
- R 7 is Cl-C3 alkyl
- R 7 is methyl
- R 8 is H.
- R 8 is halogen
- R 8 is F.
- R 8 is C 1-C6 alkyl.
- R 8 is C 1-C3 alkyl.
- R 8 is methyl
- R 9 is H.
- R 9 is C 1-C6 alkyl.
- R 9 is C 1-C3 alkyl.
- R 9 is methyl
- R 9 is C3-C6 cycloalkyl.
- R 9 is cyclopropane.
- Z 4 is CH.
- Z 4 is N.
- R 1 is methyl
- R 4 is CN
- Z 4 is CH.
- R 1 is methyl
- R 4 is CN
- Z 4 is N.
- X 2 is CH.
- X 2 is N.
- the compound of Formula I is a compound of Formula
- X 2 is CH or N
- R 1 is C 1-C6 alkyl-
- R 2 is selected from the group consisting of H, halogen, or C1-C6 alkyl- (optionally substituted with 1-3 fluoros);
- R 5 is H or C 1 -C6 alkyl-
- R 6 is H or C 1-C6 alkyl
- R 7 , R 8 , and R 9 are each independently selected from the group consisting of H, halogen, C1-C6 alkyl-, and C3-C6 cycloalkyl.
- R 1 is C1-C3 alkyl-.
- R 1 is methyl
- R 5 is H.
- R 5 is C1-C6 alkyl-.
- R 5 is methyl
- R 6 is H.
- R 6 is C1-C6 alkyl.
- R 6 is C1-C3 alkyl.
- R 6 is methyl
- R 7 is H.
- R 7 is C1-C6 alkyl.
- R 7 is C1-C3 alkyl.
- R 7 is methyl
- R 8 is H.
- R 8 is halogen
- R 8 is F.
- R 8 is C1-C6 alkyl.
- R 8 is C1-C3 alkyl.
- R 8 is methyl
- R 9 is H.
- R 9 is C1-C6 alkyl.
- R 9 is C1-C3 alkyl.
- R 9 is methyl
- R 9 is C3-C6 cycloalkyl.
- R 9 is cyclopropane.
- X 2 is CH.
- X 2 is N.
- the compound of Formula I is a compound of Formula Ij
- R 1 is C1-C6 alkyl-
- R 2 is selected from the group consisting of H, halogen, or C1-C6 alkyl- (optionally substituted with 1-3 fluoros);
- R 4 is CN
- R 6 isHorCl-C6alkyl
- R 10 at each occurrence is independently selected from the group consisting of halogen, C1-C6 alkyl-, and C1-C6 alkoxy;
- p is 1 or 2.
- R 1 is C1-C3 alkyl-.
- R 1 is methyl
- R 4 is CN
- R 6 is H.
- R 6 is C1-C6 alkyl.
- R 6 isCl-C3 alkyl.
- R 6 is methyl
- R 10 is halogen
- R 10 isF.
- R 10 isCl-C6 alkyl.
- R 10 isCl-C3 alkyl.
- R 10 is methyl
- R 10 isCl-C6 alkoxy
- R 10 is Cl-C3 alkoxy.
- R 10 is methoxy
- p is 1.
- p is 2.
- p is 2 and R 10 is F and methyl.
- Z 4 is CH.
- Z 4 is N.
- R 1 is methyl
- R 4 is CN
- Z 4 is CH.
- R 1 is methyl
- R 4 is CN
- Z 4 is N.
- X 2 is CH.
- X 2 is N.
- the compound of Formula I is a compound of Form
- X 2 is CH or N
- R 1 is Cl-C6 alkyl-
- R 2 is selected from the group consisting of H, halogen, or C1-C6 alkyl- (optionally substituted with 1-3 fluoros);
- R 5 is H or C 1 -C6 alkyl-
- R 6 is H or Cl-C6 alkyl
- R 10 at each occurrence is independently selected from the group consisting of halogen, C1-C6 alkyl-, and C1-C6 alkoxy;
- p is 1 or 2.
- R 1 is C1-C3 alkyl-.
- R 1 is methyl.
- R 5 is H.
- R 5 is C1-C6 alkyl-.
- R 5 is methyl
- R 6 is H.
- R 6 is C1-C6 alkyl.
- R 6 is Cl-C3 alkyl.
- R 6 is methyl
- R 10 is halogen
- R 10 is F.
- R 10 is C1-C6 alkyl.
- R 10 is Cl-C3 alkyl.
- R 10 is methyl
- R 10 is Cl-C6 alkoxy.
- R 10 is Cl-C3 alkoxy.
- R 10 is methoxy
- p is 1.
- p is 2.
- p is 2 and R 10 is F and methyl
- X 2 is CH.
- X 2 is N.
- methoxyethyl comprises an ethyl backbone with a methoxy substituent.
- halogen means -F (sometimes referred to herein as "fluoro" or
- C1-C3 alkyl saturated linear or branched-chain monovalent hydrocarbon radicals of one to three, one to six, two to six, or three to six carbon atoms, respectively. Examples include, but are not limited to, methyl, ethyl, 1 -propyl, isopropyl, 1 -butyl, isobutyl, sec-butyl, tert-butyl, 2-methyl- 2-propyl, pentyl, neopentyl, and hexyl.
- C1-C6 alkoxy refers to a saturated linear or branched- chain monovalent alkoxy radical of one to six carbon atoms, wherein the radical is on the oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy and tert-butoxy.
- (C1-C6 alkoxy)Cl-C6 alkyl- refers to saturated linear or branched-chain monovalent radicals of one to six carbon atoms, wherein one of the carbon atoms is substituted with a (C1-C6 alkoxy) group as defined herein. Examples include methoxymethyl (CH3OCH2-) and methoxyethyl (CH3OCH2CH2-).
- hydroxyC 1 -C6 alkyl- and "hydroxyC2-C6 alkyl-” as used herein refer to a saturated linear or branched-chain monovalent alkyl radicals of one to six or two to six carbon atoms, respectively, wherein one of the carbon atoms is substituted with a hydroxy group.
- dihydroxyC3-C6 alkyl- refers to a saturated linear or branched-chain monovalent alkyl radical of three to six carbon atoms, wherein two of the carbon atoms are substituted with a hydroxy group.
- ( ⁇ ⁇ - ⁇ alkyl-) as used herein refers to a C1-C6 alkyl as defined herein, wherein one of the carbon atoms is substituted with a R ⁇ R ⁇ - group, wherein R e and R f are as defined herein.
- C3-C6 cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
- Ar l C 1 -C6 alkyl- and " Ar*C 1 -C3 alkyl-" as used herein refer to a C 1 -
- hetAr 2 Cl-C6 alkyl- and “hetAr 2 Cl-C3 alkyl-” as used herein refer to a C1-C6 alkyl radical or C1-C3 alkyl radical, respectively, as defined herein, wherein one of the carbon atoms is substituted with an hetAr 2 group, wherein hetAr 2 is as defined herein.
- hetCy ⁇ C 1 -C6 alkyl- and "hetCy ⁇ C 1 -C3 alkyl-” as used herein refer to a C1-C6 alkyl radical or a C1-C3 radical, respectively as defined herein, wherein one of the carbon atoms is substituted with a hetCyc 1 group, wherein hetCyc 1 is as defined herein.
- tautomer refers to compounds whose structures differ markedly in arrangement of atoms, but which exist in easy and rapid equilibrium, and it is to be understood that compounds provided herein may be depicted as different tautomers, and when compounds have tautomeric forms, all tautomeric forms are intended to be within the scope of the invention, and the naming of the compounds does not exclude any tautomer.
- the compounds of Formula I include pharmaceutically acceptable salts thereof.
- pharmaceutically acceptable salt refers to salts that retain the biological effectiveness and properties of the compounds provided herein and, which are not biologically or otherwise undesirable.
- the compounds provided herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
- Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
- Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
- Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts.
- Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
- Non-limiting examples of pharmaceutically acceptable salts of compounds of Formula I include monohydrochloride, dihydrochloride, trifluoroacetic acid, and di-trifluoroacetic acid salts.
- compounds of Formula I include trifluoroacetic acid and dihydrochloride salts.
- the compounds of Formula I also include other salts of such compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula I and/or for separating enantiomers of compounds of Formula I.
- the compounds of Formula I or their salts may be isolated in the form of solvates, and accordingly that any such solvate is included within the scope of the present invention.
- compounds of Formula I and salts thereof can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
- pharmaceutically acceptable indicates that the compound, or salt or composition thereof is compatible chemically and/or toxicologically with the other ingredients comprising a formulation and/or the patient being treated therewith.
- Compounds provided herein may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. That is, an atom, in particular when mentioned in relation to a compound according to Formula I, comprises all isotopes and isotopic mixtures of that atom, either naturally occurring or synthetically produced, either with natural abundance or in an isotopically enriched form.
- the compounds provided herein therefore also comprise compounds with one or more isotopes of one or more atoms, and mixtures thereof, including radioactive compounds, wherein one or more non-radioactive atoms has been replaced by one of its radioactive enriched isotopes.
- Radiolabeled compounds are useful as therapeutic agents, e.g., cancer therapeutic agents, research reagents, e.g., assay reagents, and diagnostic agents, e.g., in vivo imaging agents. All isotopic variations of the compounds provided herein, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
- the compounds of Formula I provided herein can be prepared according to methods known in to those of skill in the art.
- the compounds of Formula I can be prepared according to the methods disclosed and described in WO 2016/127074, which is herein incorporated by reference in its entirety.
- WO 2016/127074 which is herein incorporated by reference in its entirety.
- Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the compounds provided herein.
- the compounds of Formula I provided herein can act as RET inhibitors.
- the ability of the compounds of Formula I provided herein to act as RET inhibitors can be demonstrated by assays known to those of skill in the art. For example, assays such as those described in WO 2016/127074 and PCT Application No. PCT/US16/42576, both of which are herein incorporated by reference, can be used.
- the compounds provided herein exhibit potent and selective RET inhibition.
- the compounds provided herein exhibit nanomolar potency against wild type RET and select RET mutants, including, for example, the KIF5B-RET fusion, G810R and G810S ATP cleft front or linker mutations, M918T kinase domain, and V804M, V804L, and V804E gatekeeper mutations, with minimal activity against related kinases.
- the compounds of Formula I or a pharmaceutically acceptable salt or solvate thereof selectively target a RET kinase.
- a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof can selectively target a RET kinase over another kinase or non-kinase target.
- a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof exhibits at least a 30-fold selectivity for a RET kinase over another kinase.
- a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof exhibits at least a 40-fold selectivity; at least a 50-fold selectivity; at least a 60-fold selectivity; at least a 70-fold selectivity; at least a 80-fold selectivity; at least a 90-fold selectivity; at least 100- fold selectivity; at least 200-fold selectivity; at least 300-fold selectivity; at least 400-fold selectivity; at least 500-fold selectivity; at least 600-fold selectivity; at least 700-fold selectivity; at least 800-fold selectivity; at least 900-fold selectivity; or at least 1000-fold selectivity for a RET kinase over another kinase.
- selectivity for a RET kinas exhibits at least a 30-fold selectivity for a RET
- the compounds provided herein can exhibit selectivity for a
- the selectivity for a RET kinase over a KDR kinase is observed without loss of potency for a RET kinase encoded by a RET gene including an activating mutation or a RET kinase inhibitor resistance mutation (e.g., a gatekeeper mutant).
- the selectivity over a KDR kinase is at least 10-fold (e.g., at least a 40-fold selectivity; at least a 50-fold selectivity; at least a 60-fold selectivity; at least a 70-fold selectivity; at least a 80-fold selectivity; at least a 90-fold selectivity; at least 100- fold selectivity; at least 150-fold selectivity; at least 200-fold selectivity; at least 250-fold selectivity; at least 300-fold selectivity; at least 350-fold selectivity; or at least 400-fold selectivity) as compared to the inhibition of KIF5B-RET (i.e. the compounds were more potent against KIF5B- RET than KDR).
- the selectivity for a RET kinase over a KDR kinase is about 30-fold. In some embodiments, the selectivity for a RET kinase over a KDR kinase is at least 100-fold. In some embodiments, the selectivity for a RET kinase over a KDR kinase is at least 150-fold. In some embodiments, the selectivity for a RET kinase over a KDR kinase is at least 400-fold.
- potent KDR kinase inhibition is believed to be a common feature among multikinase inhibitors (MKIs) that target RET and may be the source of the dose-limiting toxicities observed with such compounds.
- MKIs multikinase inhibitors
- inhibition of V804M was similar to that observed for wild- type RET.
- inhibition of V804M was within about 2-fold (e.g., about 5-fold, about 7- fold, about 10-fold) of inhibition of wild-type RET (i.e. the compounds were similarly potent against wild-type RET and V804M).
- selectivity for a wildtype or V804M RET kinase over another kinase is measured in an enzyme assay (e.g., an enzyme assay as provided herein).
- the compounds provided herein exhibit selective cytotoxicity to RET-mutant cells.
- the compounds provided herein exhibit brain and/or central nervous system (CNS) penetrance. Such compounds are capable of crossing the blood brain barrier and inhibiting a RET kinase in the brain and/or other CNS structures. In some embodiments, the compounds provided herein are capable of crossing the blood brain barrier in a therapeutically effective amount.
- treatment of a patient with cancer e.g., a RET-associated cancer such as a RET-associated brain or CNS cancer
- administration e.g., oral administration
- the compounds provided herein are useful for treating a primary brain tumor or metastatic brain tumor.
- the compounds of Formula I or a pharmaceutically acceptable salt or solvate thereof exhibit one or more of high GI absorption, low clearance, and low potential for drug-drug interactions.
- Compounds of Formula I are useful for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS.
- treat or “treatment” refer to therapeutic or palliative measures.
- beneficial or desired clinical results include, but are not limited to, alleviation, in whole or in part, of symptoms associated with a disease or disorder or condition, diminishment of the extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state (e.g., one or more symptoms of the disease), and remission (whether partial or total), whether detectable or undetectable.
- Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
- the terms "subject,” “individual,” or “patient,” are used interchangeably, refers to any animal, including mammals such as mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, primates, and humans.
- the patient is a human.
- the subject has experienced and/or exhibited at least one symptom of the disease or disorder to be treated and/or prevented.
- the subject has been identified or diagnosed as having a cancer with a dysregulation of a RET gene, a RET protein, or expression or activity, or level of any of the same (a RET-associated cancer) (e.g., as determined using a regulatory agency -approved, e.g., FDA-approved, assay or kit).
- the subject has a tumor that is positive for a dysregulation of a RET gene, a RET protein, or expression or activity, or level of any of the same (e.g., as determined using a regulatory agency-approved assay or kit).
- the subject can be a subject with a tumor(s) that is positive for a dysregulation of a RET gene, a RET protein, or expression or activity, or level of any of the same (e.g., identified as positive using a regulatory agency-approved, e.g., FDA-approved, assay or kit).
- the subject can be a subject whose tumors have a dysregulation of a RET gene, a RET protein, or expression or activity, or a level of the same (e.g., where the tumor is identified as such using a regulatory agency -approved, e.g., FDA-approved, kit or assay).
- the subject is suspected of having a RET-associated cancer.
- the subject has a clinical record indicating that the subject has a tumor that has a dysregulation of a RET gene, a RET protein, or expression or activity, or level of any of the same (and optionally the clinical record indicates that the subject should be treated with any of the compositions provided herein).
- the patient is a pediatric patient.
- the term "pediatric patient” as used herein refers to a patient under the age of 21 years at the time of diagnosis or treatment.
- the term “pediatric” can be further be divided into various subpopulations including: neonates (from birth through the first month of life); infants (1 month up to two years of age); children (two years of age up to 12 years of age); and adolescents (12 years of age through 21 years of age (up to, but not including, the twenty -second birthday)).
- Berhman RE Kliegman R, Arvin AM, Nelson WE. Nelson Textbook of Pediatrics, 15th Ed. Philadelphia: W.B. Saunders Company, 1996; Rudolph AM, et al. Rudolph 's Pediatrics, 21st Ed.
- a pediatric patient is from birth through the first 28 days of life, from 29 days of age to less than two years of age, from two years of age to less than 12 years of age, or 12 years of age through 21 years of age (up to, but not including, the twenty-second birthday).
- a pediatric patient is from birth through the first 28 days of life, from 29 days of age to less than 1 year of age, from one month of age to less than four months of age, from three months of age to less than seven months of age, from six months of age to less than 1 year of age, from 1 year of age to less than 2 years of age, from 2 years of age to less than 3 years of age, from 2 years of age to less than seven years of age, from 3 years of age to less than 5 years of age, from 5 years of age to less than 10 years of age, from 6 years of age to less than 13 years of age, from 10 years of age to less than 15 years of age, or from 15 years of age to less than 22 years of age.
- compounds of Formula I are useful for preventing diseases and disorders as defined herein (for example, autoimmune diseases, inflammatory diseases, and cancer).
- preventing means the prevention of the onset, recurrence or spread, in whole or in part, of the disease or condition as described herein, or a symptom thereof.
- RET-associated disease or disorder refers to diseases or disorders associated with or having a dysregulation of a RET gene, a RET kinase (also called herein RET kinase protein), or the expression or activity or level of any (e.g., one or more) of the same (e.g., any of the types of dysregulation of a RET gene, a RET kinase, a RET kinase domain, or the expression or activity or level of any of the same described herein).
- Non-limiting examples of a RET-associated disease or disorder include, for example, cancer and gastrointestinal disorders such as irritable bowel syndrome (IBS).
- RET-associated cancer refers to cancers associated with or having a dysregulation of a RET gene, a RET kinase (also called herein RET kinase protein), or expression or activity, or level of any of the same.
- RET-associated cancer is described herein.
- the phrase "dysregulation of a RET gene, a RET kinase, or the expression or activity or level of any of the same” refers to a genetic mutation (e.g., a chromosomal translocation that results in the expression of a fusion protein including a RET kinase domain and a fusion partner, a mutation in a RET gene that results in the expression of a RET protein that includes a deletion of at least one amino acid as compared to a wildtype RET protein, a mutation in a RET gene that results in the expression of a RET protein with one or more point mutations as compared to a wildtype RET protein, a mutation in a RET gene that results in the expression of a RET protein with at least one inserted amino acid as compared to a wildtype RET protein, a gene duplication that results in an increased level of RET protein in a cell, or a mutation in a regulatory sequence (e.g., a promoter and
- a dysregulation of a RET gene, a RET protein, or expression or activity, or level of any of the same can be a mutation in a RET gene that encodes a RET protein that is constitutively active or has increased activity as compared to a protein encoded by a RET gene that does not include the mutation.
- a dysregulation of a RET gene, a RET protein, or expression or activity, or level of any of the same can be the result of a gene or chromosome translocation which results in the expression of a fusion protein that contains a first portion of RET that includes a functional kinase domain, and a second portion of a partner protein (i.e., that is not RET).
- dysregulation of a RET gene, a RET protein, or expression or activity or level of any of the same can be a result of a gene translocation of one RET gene with another non-RET gene.
- Non-limiting examples of fusion proteins are described in Table 1.
- Non-limiting examples of RET kinase protein point mutations/insertions/deletions are described in Tables 2 and 2a.
- Additional examples of RET kinase protein mutations are RET inhibitor resistance mutations.
- Non-limiting examples of RET inhibitor resistance mutations are described in Tables 3 and 4.
- dysregulation of a RET gene, a RET kinase, or the expression or activity or level of any of the same can be caused by an activating mutation in a RET gene (see, e.g., chromosome translocations that result in the expression of any of the fusion proteins listed in Table 1).
- dysregulation of a RET gene, a RET kinase, or the expression or activity or level of any of the same can be caused by a genetic mutation that results in the expression of a RET kinase that has increased resistance to inhibition by a RET kinase inhibitor and/or a multi-kinase inhibitor (MKI), e.g., as compared to a wildtype RET kinase (see, e.g., the amino acid substitutions in Tables 3 and 4).
- MKI multi-kinase inhibitor
- the exemplary RET kinase point mutations, insertions, and deletions shown in Tables 2 and 2a can be caused by an activating mutation and/or can result in the expression of a RET kinase that has increased resistance to inhibition by a RET kinase inhibitor and/or a multi-kinase inhibitor (MKI).
- MKI multi-kinase inhibitor
- activating mutation describes a mutation in a RET kinase gene that results in the expression of a RET kinase that has an increased kinase activity, e.g., as compared to a wildtype RET kinase, e.g., when assayed under identical conditions.
- an activating mutation can result in the expression of a fusion protein that includes a RET kinase domain and a fusion partner.
- an activating mutation can be a mutation in a RET kinase gene that results in the expression of a RET kinase that has one or more (e.g., two, three, four, five, six, seven, eight, nine, or ten) amino acid substitutions (e.g., any combination of any of the amino acid substitutions described herein) that has increased kinase activity, e.g., as compared to a wildtype RET kinase, e.g., when assayed under identical conditions.
- one or more amino acid substitutions e.g., any combination of any of the amino acid substitutions described herein
- an activating mutation can be a mutation in a RET kinase gene that results in the expression of a RET kinase that has one or more (e.g., two, three, four, five, six, seven, eight, nine, or ten) amino acids deleted, e.g., as compared to a wildtype RET kinase, e.g., when assayed under identical conditions.
- an activating mutation can be a mutation in a RET kinase gene that results in the expression of a RET kinase that has at least one (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 18, or at least 20) amino acid inserted as compared to a wildtype RET kinase, e.g., the exemplary wildtype RET kinase described herein, e.g., when assayed under identical conditions. Additional examples of activating mtuations are known in the art.
- wildtype or wild-type describes a nucleic acid (e.g., a RET gene or a RET mRNA) or protein (e.g., a RET protein) that is found in a subject that does not have a RET- associated disease, e.g., a RET-associated cancer (and optionally also does not have an increased risk of developing a RET-associated disease and/or is not suspected of having a RET-associated disease), or is found in a cell or tissue from a subject that does not have a RET-associated disease, e.g., a RET-associated cancer (and optionally also does not have an increased risk of developing a RET-associated disease and/or is not suspected of having a RET-associated disease).
- a RET-associated disease e.g., a RET-associated cancer
- regulatory agency refers to a country's agency for the approval of the medical use of pharmaceutical agents with the country.
- FDA U.S. Food and Drug Administration
- a method of treating cancer e.g., a RET-associated cancer
- the method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof.
- methods for treating a RET-associated cancer in a patient in need of such treatment comprising a) detecting a dysregulation of a RET gene, a RET kinase, or the expression or activity or level of any of the same in a sample from the patient; and b) administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof.
- the dysregulation of a RET gene, a RET kinase, or the expression or activity or level of any of the same includes one or more fusion proteins.
- RET gene fusion proteins are described in Table 1.
- the fusion protein is KIF5B-RET.
- the dysregulation of a RET gene, a RET kinase, or the expression or activity or level of any of the same includes one or more RET kinase protein point mutations/insertions.
- Non-limiting examples of RET kinase protein point mutations/insertions/deletions are described in Tables 2 and 2a.
- the RET kinase protein point mutations/insertions/deletions are selected from the group consisting of M918T, M918V, C634W, V804L, and V804M.
- the cancer in some embodiments of any of the methods or uses described herein, the cancer
- the cancer (e.g., RET-associated cancer) is a hematological cancer.
- the cancer e.g., RET-associated cancer
- the cancer is a solid tumor.
- the cancer e.g., RET- associated cancer
- the cancer is a solid tumor.
- the cancer e.g., RET-associated cancer
- lung cancer e.g., small cell lung carcinoma or non-small cell lung carcinoma
- thyroid cancer e.g., papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, or refractory differentiated thyroid cancer
- thyroid ademona endocrine gland neoplasms
- lung adenocarcinoma bronchioles lung cell carcinoma
- multiple endocrine neoplasia type 2A or 2B (MEN2A or MEN2B, respectively)
- pheochromocytoma parathyroid hyperplasia
- breast cancer mammary cancer
- mammary carcinoma mammary neoplasm
- colorectal cancer e.g., metastatic colorectal cancer
- papillary renal cell carcinoma ganglioneuromatosis of the gastroenteric mucosa
- inflammatory myofibroblastic tumor or cervical cancer
- the cancer e.g., RET-associated cancer
- ALL acute lymphoblastic leukemia
- AML acute myeloid leukemia
- cancer in adolescents adrenocortical carcinoma
- anal cancer appendix cancer
- astrocytoma atypical teratoid/rhabdoid tumor
- basal cell carcinoma bile duct cancer
- bladder cancer bone cancer
- brain stem glioma brain tumor
- breast cancer bronchial tumor
- Burkitt lymphoma carcinoid tumor
- unknown primary carcinoma cardiac tumors, cervical cancer, childhood cancers, chordoma
- CML chronic myelogenous leukemia
- chronic myeloproliferative neoplasms neoplasms by site, neoplasms, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T
- a hematological cancer is selected from the group consisting of leukemias, lymphomas (non- Hodgkin's lymphoma), Hodgkin's disease (also called Hodgkin's lymphoma), and myeloma, for instance, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (C L), acute undifferentiated leukemia (AUL), anaplastic large-cell lymphoma (ALCL), prolymphocytic leukemia (PML), juvenile myelomonocyctic leukemia (JMML), adult T-cell ALL, A hematological cancers that are RET-associated cancers
- ALL acute lymphocytic leukemia
- AML
- hematological cancers include myeloproliferative disorders (MPD) such as polycythemia vera (PV), essential thrombocytopenia (ET) and idiopathic primary myelofibrosis (IMF/IPF/PMF).
- MPD myeloproliferative disorders
- PV polycythemia vera
- ET essential thrombocytopenia
- IMF/IPF/PMF idiopathic primary myelofibrosis
- the hematological cancer e.g., the hematological cancer that is a RET-associated cancer
- AML or CMML.
- the cancer is a solid tumor.
- solid tumors e.g., solid tumors that are RET-associated cancers
- the cancer is selected from the group consisting of lung cancer, papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, refractory differentiated thyroid cancer, multiple endocrine neoplasia type 2A or 2B (MEN2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer, colorectal cancer, papillary renal cell carcinoma, ganglioneuromatosis of the gastroenteric mucosa, and cervical cancer.
- the patient is a human.
- a method for treating a patient diagnosed with or identified as having a RET-associated cancer comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof as defined herein.
- Dysregulation of a RET kinase, a RET gene, or the expression or activity or level of any (e.g., one or more) of the same can contribute to tumorigenesis.
- a dysregulation of a RET kinase, a RET gene, or expression or activity or level of any of the same can be a translocation, overexpression, activation, amplification, or mutation of a RET kinase, a RET gene, or a RET kinase domain.
- Translocation can include a gene translocation resulting in the expression of a fusion protein that includes a RET kinase domain and a fusion partner.
- a fusion protein can have increased kinase activity as compared to a wildtype RET protein.
- a mutation in a RET gene can involve mutations in the RET ligand-binding site, extracellular domains, kinase domain, and in regions involved in protein: protein interactions and downstream signaling.
- a mutation (e.g., an activating mutation) in a RET gene can result in the expression of a RET kinase having one or more (e.g., two, three, four, five, six, seven, eight, nine, or ten) amino acid substitutions (e.g., one or more amino acid substitutions in the kinase domain (e.g., amino acid positions 723 to 1012 in a wildtype RET protein), a gatekeeper amino acid (e.g., amino acid position 804 in a wildtype RET protein), the P-loop (e.g., amino acid positions 730-737 in a wildtype RET protein), the DFG motif (e.g., amino acid positions 892-894 in a wildtype RET protein), ATP cleft solvent front amino acids (e.g., amino acid positions 758, 811, and 892 in a wildtype RET protein), the activation loop (e.g., amino acid positions 891-916 in a wildtype
- a mutation can be a gene amplification of a RET gene.
- a mutation (e.g., an activating mutation) in a RET gene can result in the expression of a RET kinase that lacks at least one amino acid (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 amino acids) as compared to a wildtype RET protein.
- at least one amino acid e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 amino acids
- dyregulation of a RET kinase can be increased expression (e.g., increased levels) of a wildtype RET kinase in a mammalian cell due to aberrant cell signaling and/or dysregulated autocrine/paracrine signaling (e.g., as compared to a control non-cancerous cell).
- a mutation (e.g., an activating mutation) in a RET gene can result in the expression of a RET kinase that has at least one amino acid (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 amino acids) inserted as compared to a wildtype RET protein.
- at least one amino acid e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 amino acids
- dyregulation of a RET kinase can be increased expression (e.g., increased levels) of a wildtype RET kinase in a mammalian cell (e.g., as compared to a control non-cancerous cell), e.g., due to aberrant cell signaling and/or dysregulated autocrine/paracrine signaling.
- Other dysregulations can include RET mRNA splice variants.
- the wildtype RET protein is the exemplary wildtype RET protein described herein.
- the dysregulation of a RET gene, a RET kinase, or expression or activity or level of any of the same includes overexpression of wild-type RET kinase (e.g., leading to autocrine activation).
- the dysregulation of a RET gene, a RET kinase protein, or expression or activity or level of any of the same includes overexpression, activation, amplification, or mutation in a chromosomal segment comprising the RET gene or a portion thereof, including, for example, the kinase domain portion, or a portion capable of exhibiting kinase activity.
- the dysregulation of a RET gene, a RET kinase protein, or expression or activity or level of any of the same includes one or more chromosome translocations or inversions resulting in a RET gene fusion.
- the dysregulation of a RET gene, a RET kinase protein, or expression or activity or level of any of the same is a result of genetic translocations in which the expressed protein is a fusion protein containing residues from a non-RET partner protein, and includes a minimum of a functional RET kinase domain.
- Non-limiting examples of RET fusion proteins are shown in Table 1.
- NCOA4 also Papillary Thyroid Cancer 21 , called PTC3, NSCLC, Colon Cancer
- Adenocarcinoma 15 Adenocarcinoma 15 ;
- TRIM33 also NSCLC, Papillary Thyroid called PTC7 and Cancer
- ERC1 also called Papillary Thyroid Cancer
- MBDl also known Papillary Thyroid Cancer as PCM1
- PCM1 Papillary Thyroid Cancer
- PRKAR1 A also Papillary Thyroid Cancer called PTC2
- TRIM24 also Papillary Thyroid Cancer called PTC6
- KTN1 also called Papillary Thyroid Cancer PTC8 .
- GOLGA5 also Papillary Thyroid Cancer, called PTC5
- PTC5 Papillary Thyroid Cancer
- KIAA1468 also Papillary Thyroid Cancer, called PTC9 and Lung Adenocarcinoma 8 ' 12 RFG9
- TRIM27 also Papillary Thyroid Cancer called RFP
- KIAA1217 also Papillary Thyroid Cancer 10, called SKT 13
- the dysregulation of a RET gene, a RET kinase, or expression or activity or level of any of the same includes one or more deletions (e.g., deletion of an amino acid at position 4), insertions, or point mutation(s) in a RET kinase.
- the dysregulation of a RET gene, a RET kinase, or expression or activity or level of any of the same includes a deletion of one or more residues from the RET kinase, resulting in constitutive activity of the RET kinase domain.
- the dysregulation of a RET gene, a RET kinase, or expression or activity or level of any of the same includes at least one point mutation in a RET gene that results in the production of a RET kinase that has one or more amino acid substitutions, insertions, or deletions as compared to the wild-type RET kinase (see, for example, the point mutations listed in Table 2).
- Amino acid position 32 (e.g., S32L)
- Amino acid position 34 e.g., D34S
- Amino acid position 40 (e.g., L40P)
- Amino acid position 56 (e.g., L56M) 30
- Amino acid position 64 (e.g., P64L)
- Amino acid position 67 (e.g., R67H)
- Amino acid position 114 (e.g., Rl 14H)
- Amino acid position 136 (e.g., glutamic acid to stop codon)
- Amino acid position 145 (e.g., V145G)
- Amino acid position 180 (e.g., arginine to stop codon)
- Amino acid position 292 e.g., V292M
- Amino acid position 321 e.g., G321R
- Amino acid position 330 (e.g., R330Q)
- Amino acid position 338 e.g., T338I
- Amino acid position 360 e.g., R360W
- Amino acid position 373 (e.g., alanine to frameshift)
- Amino acid position 423 (e.g., G423R) 27
- Amino acid position 446 (e.g., G446R) 28
- Amino acid position 510 e.g., A510V
- Amino acid position 511 e.g., E51 IK
- Amino acid position 513 e.g., G513D 7*
- Amino acid position 515 (e.g., C515S, C515W 4 )
- Amino acid position 525 (e.g., R525W) 7*
- Amino acid position 531 e.g., C531R, or 9 base pair duplication 2 .
- Amino acid position 532 (e.g., duplication) 2
- Amino acid position 533 e.g., G533C, G533S
- Amino acid position 550 (e.g., G550E)
- Amino acid position 591 e.g., V591I
- Amino acid position 593 e.g., G593E
- Amino acid position 595 e.g., E595D and E595A 18
- Amino acid position 600 e.g., R600Q
- Amino acid position 602 (e.g., 1602 V) 6
- Amino acid position 603 (e.g., K603Q, K603E 2 )
- Amino acid position 606 (e.g., Y606C)
- Amino acid position 609 e.g., C609Y, C609S, C609G,
- Amino acid position 611 e.g., C611R, C611 S, C611G,
- Amino acid position 616 (e.g., E616Q) 23
- Amino acid position 618 e.g., C618S, C618Y, C618R,
- Amino acid position 619 e.g., F619F
- Amino acid position 620 (e.g., C620S, C620W,
- Amino acid position 623 (e.g., E623K)
- Amino acid position 624 e.g., D624N
- Amino acid position 630 (e.g., C630A, C630R, C630S,
- Amino acid position 631 e.g., D631N, D631Y,
- Amino acid position 632 (e.g., E632K, E632G 5 ' u )
- Amino acid position 633 (e.g., 9 base pair duplication 2 )
- Amino acid position 634 (e.g., C634W, C634Y,
- Amino acid position 635 e.g., R635G
- Amino acid position 636 (e.g., T636P 2 , T636M 4 )
- Amino acid position 640 (e.g., A640G)
- Amino acid position 641 (e.g., A641 S, A641T 8 )
- Amino acid position 648 (e.g., V648I)
- Amino acid position 649 (e.g., S649L) 28
- Amino acid position 664 e.g., A664D
- Amino acid position 665 e.g., H665Q
- Amino acid position 666 e.g., K666E, K666M,
- Amino acid position 686 e.g. S686N
- Amino acid position 689 (e.g. S689T) 18
- Amino acid position 691 e.g. G691 S
- Amino acid position 694 (e.g. R694Q)
- Amino acid position 700 e.g. M700L
- Amino acid position 706 e.g. V706M, V706A
- Amino acid position 713 splice variant e.g., E713K 6
- Amino acid position 732 (e.g. E732K) 20
- Amino acid position 736 (e.g. G736R) 6
- Amino acid position 748 e.g. G748C
- Amino acid position 750 (e.g. A750P)
- Amino acid position 765 e.g. S765P
- Amino acid position 766 (e.g. P766S, P766M 6 )
- Amino acid position 768 (e.g. E768Q, E768D)
- Amino acid position 769 (e.g. L769L)
- Amino acid position 770 (e.g. R770Q)
- Amino acid position 771 e.g. D771N
- Amino acid position 777 (e.g. N777S)
- Amino acid position 778 (e.g. V778I)
- Amino acid position 781 e.g. Q781R
- Amino acid position 788 (e.g. I788I 32 )
- Amino acid position 790 e.g. L790F
- Amino acid position 791 (e.g. Y791F, Y791N 24 )
- Amino acid position 804 (e.g., V804L 15 ' 16 , V804M 15 '
- Amino acid position 805 e.g., E805K
- Amino acid position 806 (e.g., Y806F, Y806S 12 ,
- Amino acid position 810 e.g., G810R 12 , G810S 12 ,
- Amino acid position 818 (e.g. E818K)
- Amino acid position 819 e.g. S819I
- Amino acid position 823 e.g. G823E
- Amino acid position 826 (e.g. Y826M, Y826S) 10
- Amino acid position 833 e.g. R833C
- Amino acid position 836 (e.g. S836S) 19
- Amino acid position 841 e.g. P841L, P841P
- Amino acid position 843 (e.g. E843D)
- Amino acid position 844 e.g. R844W, R844Q,
- Amino acid position 848 (e.g. M848T)
- Amino acid position 852 e.g. I852M
- Amino acid position 865 (e.g. L865V) 12
- Amino acid position 866 (e.g. A866W) 33
- Amino acid position 870 (e.g. L870F) 12
- Amino acid position 873 (e.g. R873W)
- Amino acid position 876 e.g. A876V
- Amino acid position 881 e.g. L881V
- Amino acid position 883 e.g. A883F, A883S, A883T
- Amino acid position 884 (e.g. E884K)
- Amino acid position 886 (e.g. R886W)
- Amino acid position 891 (e.g. S891A, S891 S 32 )
- Amino acid position 898 e.g., D898V
- Amino acid position 900 (e.g. Y900F) 22
- Amino acid position 901 (e.g. E901K)
- Amino acid position 904 (e.g. S904F, S904S, S904C 2 )
- Amino acid position 905 (e.g. Y905F) 22
- Amino acid position 907 e.g. K907E, K907M
- Amino acid position 908 (e.g. R908K)
- Amino acid position 911 e.g. G911D
- Amino acid position 912 e.g. R912P, R912Q
- Amino acid position 918 (e.g M918T 2 , M918V, M918L 6 ) (e g., causing MTC)
- Amino acid position 919 e.g. A919V
- Amino acid position 921 (e.g. E921K)
- Amino acid position 922 e.g. S922P, S922Y
- Amino acid position 930 (e.g. T930M)
- Amino acid position 961 e.g. F961L
- Amino acid position 972 (e.g. R972G)
- Amino acid position 981 (e.g. Y981F) 22
- Amino acid position 982 (e.g., R982C)
- Amino acid position 1009 e.g., M1009V
- Amino acid position 1015 (e.g., Y1015F) 22
- Amino acid position 1017 e.g., D1017N
- Amino acid position 1041 e.g., V1041G
- Amino acid position 1064 (e.g., M1064T)
- Amino acid position 1096 (e.g., Y1096F)
- Amino acid position 1109 (e.g., Ml 109T) 34
- Amino acid positions 791 and 852 e.g., Y791F +
- Amino acid positions 634 and 852 e.g., C634R +
- the RET kinase mutations shown may be activating mutations and/or confer increased resistance of the RET kinase to a RET kinase inhibitor and/or a multi-kinase inhibitor (MKI), e.g., as compared to a wildtype RET kinase.
- MKI multi-kinase inhibitor
Abstract
L'invention concerne des composés de formule (I) : et des sels ou solvates pharmaceutiquement acceptables de ceux-ci. Dans la formule, A, B, Y, X1, X2, X3, X4, R1, R2, n et m sont tels que définis dans la description. Les composés de l'invention sont des inhibiteurs de la kinase RET et sont utiles dans le traitement et la prévention de maladies qui peuvent être traitées avec un inhibiteur de la kinase RET, y compris des maladies et des troubles associés à RET.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762447858P | 2017-01-18 | 2017-01-18 | |
US62/447,858 | 2017-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018136663A1 true WO2018136663A1 (fr) | 2018-07-26 |
Family
ID=61231308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/014281 WO2018136663A1 (fr) | 2017-01-18 | 2018-01-18 | Inhibiteurs de ret |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018136663A1 (fr) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020033838A2 (fr) | 2018-08-10 | 2020-02-13 | Blueprint Medicines Corporation | Traitement du cancer à egfr mutant |
WO2020083332A1 (fr) * | 2018-10-24 | 2020-04-30 | 南京明德新药研发有限公司 | Dérivé de pyrimidine tenant lieu d'inhibiteur ret |
CN111285882A (zh) * | 2018-12-07 | 2020-06-16 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物、包含其的药物组合物及其制备方法和用途 |
WO2020188015A1 (fr) | 2019-03-21 | 2020-09-24 | Onxeo | Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer |
WO2020200314A1 (fr) * | 2019-04-03 | 2020-10-08 | 南京明德新药研发有限公司 | Dérivé spiro contenant de l'azote utilisé en tant qu'inhibiteur de ret |
WO2020207419A1 (fr) | 2019-04-12 | 2020-10-15 | 浙江海正药业股份有限公司 | Dérivé de pipérazine amide, son procédé de préparation et son utilisation en médecine |
WO2021089791A1 (fr) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
CN113784963A (zh) * | 2019-05-20 | 2021-12-10 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
CN113853375A (zh) * | 2019-05-21 | 2021-12-28 | 株式会社沃若诺伊 | 含n杂芳基衍生物及包含其作为活性成分的用于预防或治疗癌症的药物组合物 |
US11273160B2 (en) | 2018-04-03 | 2022-03-15 | Blueprint Medicines Corporation | RET inhibitor for use in treating cancer having a RET alteration |
US11279688B2 (en) | 2015-11-02 | 2022-03-22 | Blueprint Medicines Corporation | Inhibitors of RET |
WO2023239422A2 (fr) | 2021-10-22 | 2023-12-14 | University Of Houston System | Méthodes et compositions pour traiter une lésion inflammatoire chronique, une métaplasie, une dysplasie et des cancers des tissus épithéliaux |
US11963958B2 (en) | 2020-10-02 | 2024-04-23 | Rigel Pharmaceuticals, Inc. | RET inhibitor for use in treating cancer having a RET alteration |
Citations (235)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987005297A1 (fr) | 1986-03-03 | 1987-09-11 | The University Of Chicago | Derives de cephalosporines |
WO1997044356A2 (fr) | 1996-05-08 | 1997-11-27 | Biogen, Inc. | Test diagnostique de detection de la schizophrenie faisant appel a de la miacine |
US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
WO2001016169A2 (fr) | 1999-09-01 | 2001-03-08 | Biogen, Inc. | COMPOSITIONS A BASE DE LIGAND 5 (RetL5) ET SES UTILISATIONS |
WO2001062273A1 (fr) | 2000-02-22 | 2001-08-30 | Hannu Sariola | Utilisation de composes de la famille gdnf pour fabriquer des produits destines au traitement de tumeurs testiculaires |
US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
WO2003020698A2 (fr) | 2001-09-06 | 2003-03-13 | Prochon Biotech Ltd. | Inhibiteurs de la tyrosine kinase |
US20040185547A1 (en) | 1996-08-21 | 2004-09-23 | Sugen, Inc. | Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases |
US6861509B1 (en) | 1996-05-08 | 2005-03-01 | Biogen, Inc. | Antibodies to Ret and RetL3 |
WO2005044835A1 (fr) | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | Procedes de preparation de derives 7-(2'-$g(b)-d-ribofuranosyl substitue)-4-(nr2r3)-5-(ethyn-1-yl substitue)-pyrrolo[2,3-d]pyrimidine |
WO2005070431A1 (fr) | 2004-01-22 | 2005-08-04 | Novartis Ag | Derives de pyrazolo[1,5-a]pyrimidin-7-yl-amine destines a etre utilises dans le traitement de maladies dependantes de la proteine kinase |
US20050209195A1 (en) | 2004-01-20 | 2005-09-22 | Cell Therapeutics Europe S.R.I | Indolinone derivatives |
US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
US20060183900A1 (en) | 2004-10-29 | 2006-08-17 | Shenlin Huang | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
WO2006089298A2 (fr) | 2005-02-18 | 2006-08-24 | Attenuon, Llc | Derives de diazepine fusionnes pyrimidine et pteridines fusionnees indole |
WO2006123113A2 (fr) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Composes chimiques |
WO2006130613A2 (fr) | 2005-05-31 | 2006-12-07 | The Pfahl Family Trust (Dated 9 July 1996) | Derives de biarylheterocycle substitues utilises comme inhibiteurs de la proteine kinase pour le traitement du cancer et d'autres maladies |
WO2006131952A1 (fr) | 2005-06-07 | 2006-12-14 | Lay Line Genomics S.P.A. | Traitement analgesique a effet prolonge |
WO2007002325A1 (fr) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Composes et methodes de modulation de la kinase et instructions afferentes |
WO2007022999A1 (fr) | 2005-08-25 | 2007-03-01 | Creabilis Therapeutics S.P.A. | Conjugues polymeres de k-252a et leurs derives |
WO2007054357A1 (fr) | 2005-11-14 | 2007-05-18 | 4Sc Ag | Analogues de thiazole et leurs utilisations |
WO2007057399A2 (fr) | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Traitement du cancer |
WO2007057397A1 (fr) | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Traitement du cancer |
US20070117800A1 (en) | 2005-11-03 | 2007-05-24 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
US20070149523A1 (en) | 2005-11-14 | 2007-06-28 | Jan Ehlert | Thiazole Analogues and Uses Thereof |
WO2007087245A2 (fr) | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Inhibition de la tyrosine kinase ret |
WO2007109045A1 (fr) | 2006-03-16 | 2007-09-27 | Novartis Ag | composes organiques |
WO2007110344A1 (fr) | 2006-03-27 | 2007-10-04 | Nerviano Medical Sciences S.R.L. | Dérivés de pyrrole, de thiophène et de furane substitués par un pyridyle et dérivés de pyrrole, de thiophène et de furane substitués par un pyrimidinyle en tant qu'inhibiteurs de kinase |
US20070265274A1 (en) | 2002-07-24 | 2007-11-15 | Fagin James A | 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases |
US7384632B2 (en) | 2000-06-22 | 2008-06-10 | Genentech, Inc. | Agonist anti-trk-C monoclonal antibodies |
WO2008080001A2 (fr) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Composés et procédés pour la modulation de kinases et indications pour celle-ci |
WO2008079903A1 (fr) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Dérivés de pyrrolo [2, 3-b] pyridine utilisés comme modulateurs de kinase |
WO2008079909A1 (fr) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Composés et méthodes de modulation des kinases, et indications connexes |
US20080199426A1 (en) | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
US20080234267A1 (en) | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
US20080234284A1 (en) | 2005-07-21 | 2008-09-25 | Patricia Imbach | Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors |
US20080234276A1 (en) | 2005-02-01 | 2008-09-25 | Sentinel Oncology Limited | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors |
US20080262021A1 (en) | 2003-11-21 | 2008-10-23 | Novartis Ag | 1H-Imidazoquinoline Derivatives as Prote In Kinase Inhibitors |
US20080275054A1 (en) | 2005-11-30 | 2008-11-06 | Philipp Holzer | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors |
US20080287427A1 (en) | 2004-09-15 | 2008-11-20 | Guido Bold | Bicyclic Amides as Kinase Inhibitors |
US7465726B2 (en) | 2004-08-02 | 2008-12-16 | Osi Pharmaceuticals, Inc. | Substituted pyrrolo[2.3-B]pyridines |
US20080312192A1 (en) | 2003-11-28 | 2008-12-18 | Guido Bold | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases |
US20080319005A1 (en) | 2005-04-14 | 2008-12-25 | Guido Bold | Phenylacetamides Suitable as Protein Kinase Inhibitors |
US20090012045A1 (en) | 2007-06-26 | 2009-01-08 | Rigel Pharmaceuticals, Inc. | Methods of Treating Cell Proliferative Disorders |
WO2009007748A2 (fr) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Composés 945 |
WO2009012283A1 (fr) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Composés et procédés pour la modulation des kinases et leurs indications |
WO2009013126A1 (fr) | 2007-07-20 | 2009-01-29 | Nerviano Medical Sciences S.R.L. | Dérivés d'indazole substitués actifs comme inhibiteurs de kinases |
WO2009017838A2 (fr) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinaisons d'inhibiteurs jak-2 et d'autres agents |
US20090048249A1 (en) | 2005-05-31 | 2009-02-19 | George Chiu | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
WO2009023978A1 (fr) | 2007-08-17 | 2009-02-26 | Oncalis Ag | Composés pyrazolo[3,4-d]pyrimidines et leur utilisation en tant que modulateurs de protéine kinase |
WO2009042646A1 (fr) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Agents antiprolifératifs |
US7514446B2 (en) | 2003-02-20 | 2009-04-07 | Smithkline Beecham Corporation | Pyrimidine compounds |
WO2009053442A1 (fr) | 2007-10-23 | 2009-04-30 | Novartis Ag | Utilisation d'anticorps trkb pour le traitement de troubles respiratoires |
US20090130229A1 (en) | 2002-07-23 | 2009-05-21 | Cell Therapeutics, Inc. | Antitumor uses of compound |
US20090143399A1 (en) | 2003-10-14 | 2009-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
WO2009071480A2 (fr) | 2007-12-04 | 2009-06-11 | Nerviano Medical Sciences S.R.L. | Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase |
WO2009092049A1 (fr) | 2008-01-17 | 2009-07-23 | Irm Llc | Anticorps anti-trkb améliorés |
US20090209496A1 (en) | 2008-02-15 | 2009-08-20 | David Chaplin | Methods and compositions for enhancing the efficacy of rtk inhibitors |
US20090215761A1 (en) | 2005-04-15 | 2009-08-27 | Cylene Pharmaceuticals, Inc. | Quinobenzoxazine analogs and methods of using thereof |
US20090227556A1 (en) | 2008-01-31 | 2009-09-10 | Eisai R&D Management Co., Ltd. | Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives |
WO2009118411A2 (fr) | 2008-03-28 | 2009-10-01 | Nerviano Medical Sciences S.R.L. | Dérivés actifs de 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one en tant qu’inhibiteurs de kinase, procédé pour leur préparation et compositions pharmaceutiques les contenant |
WO2009143024A2 (fr) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Composés et procédés de modulation des kinases, et indications associées |
WO2009143018A2 (fr) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Composés et procédés de modulation des kinases, et indications associées |
US20090312321A1 (en) | 2006-05-15 | 2009-12-17 | Irm Llc | Compositions and methods for fgf receptor kinases inhibitors |
US20100004239A1 (en) | 2006-01-27 | 2010-01-07 | Peng Cho Tang | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors |
US20100069395A1 (en) | 2006-10-30 | 2010-03-18 | Patricia Imbach | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors |
WO2010033941A1 (fr) | 2008-09-22 | 2010-03-25 | Array Biopharma Inc. | Composés imidazo[1,2b]pyridazine substitués comme inhibiteurs de kinases trk |
WO2010031816A1 (fr) | 2008-09-19 | 2010-03-25 | Nerviano Medical Sciences S.R.L. | Dérivés de 3,4-dihydro-2h-pyrrolo[1,2-a]pyrazine-1-one |
US20100075916A1 (en) | 2008-09-05 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases |
US20100081675A1 (en) | 2008-09-26 | 2010-04-01 | National Health Research Institutes | Fused multicyclic compounds as protein kinase inhibitors |
WO2010048314A1 (fr) | 2008-10-22 | 2010-04-29 | Array Biopharma Inc. | Composés de pyrazolo[1,5-a]pyrimidine substitués comme inhibiteurs de la trk kinase |
WO2010058006A1 (fr) | 2008-11-24 | 2010-05-27 | Nerviano Medical Sciences S.R.L. | Inhibiteur de cdk (kinase cycline-dépendante) pour le traitement d'un mésothéliome |
US20100152219A1 (en) | 2003-11-17 | 2010-06-17 | Astrazeneca R&D | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
US20100173954A1 (en) | 2007-01-19 | 2010-07-08 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
US20100209488A1 (en) | 2007-07-16 | 2010-08-19 | The Regents Of The University Of California | Protein kinase modulating compounds and methods for making and using them |
US7795273B2 (en) | 2005-12-08 | 2010-09-14 | Novartis Ag | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors |
WO2010111527A1 (fr) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines en tant qu'inhibiteurs de la kinase et leur utilisation médicale |
US20100280012A1 (en) | 2009-04-29 | 2010-11-04 | Industrial Technology Research Institute | Azaazulene compounds |
WO2010145998A1 (fr) | 2009-06-15 | 2010-12-23 | Nerviano Medical Sciences S.R.L. | Dérivés de pyrimidinylpyrrolopyridinone substitués, procédé pour leur préparation et leur utilisation en tant qu'inhibiteurs de kinase |
WO2011006074A1 (fr) | 2009-07-09 | 2011-01-13 | Array Biopharma Inc. | Composés pyrazolo[1,5-a]pyrimidines substituées en tant qu'inhibiteurs des trk kinases |
US20110046370A1 (en) | 2009-08-20 | 2011-02-24 | Korea Institute Of Science And Technology | 1,3,6-substituted indole derivatives having inhibitory activity for protein kinase |
US20110189167A1 (en) | 2007-04-20 | 2011-08-04 | Flynn Daniel L | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases |
WO2011092120A1 (fr) | 2010-01-29 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | Dérivés de 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one comme modulateurs de protéines kinases |
US20110195072A1 (en) | 2006-09-12 | 2011-08-11 | Anne Boulay | Non-neuroendocrine cancer therapy |
US20110212053A1 (en) | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
WO2011133637A2 (fr) | 2010-04-21 | 2011-10-27 | Plexxikon, Inc. | Compositions et méthodes de modulation des kinases et leurs indications |
US20110269739A1 (en) | 2009-10-29 | 2011-11-03 | Oscotec, Inc. | Kinase inhibitors |
US20110281841A1 (en) | 2009-11-13 | 2011-11-17 | Oscotec, Inc. | Kinase Inhibitors |
WO2011146336A1 (fr) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Composés macrocycliques en tant qu'inhibiteurs de kinase trk |
US8067434B2 (en) | 2003-12-19 | 2011-11-29 | Plexxikon Inc. | Compounds and methods for development of Ret modulators |
US8106069B2 (en) | 2003-12-24 | 2012-01-31 | Pfizer Italia S.R.L. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them |
US8129374B2 (en) | 2006-03-17 | 2012-03-06 | Ambit Bioscience Corporation | Method of using imidazolothiazole compounds for the treatment of disease |
US20120065233A1 (en) | 2008-03-19 | 2012-03-15 | Vlad Edward Gregor | Tyrosine kinase inhibitors |
WO2012034095A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions comme inhibiteurs de trk |
WO2012034091A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions à titre d'inhibiteurs de trk |
US20120070410A1 (en) | 2008-11-06 | 2012-03-22 | Apuy Julius L | Imidazolothiazole compounds and methods of use thereof |
WO2012047017A2 (fr) | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant |
WO2012053606A1 (fr) | 2010-10-22 | 2012-04-26 | アステラス製薬株式会社 | Carboxamide arylaminohétérocyclique |
US8198298B2 (en) | 2003-12-24 | 2012-06-12 | Pfizer Italia S.R.L. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors |
WO2012101032A1 (fr) | 2011-01-26 | 2012-08-02 | Nerviano Medical Sciences S.R.L. | Dérivés pyrrolo tricycliques, leur procédé de préparation et leur utilisation à titre d'inhibiteurs de kinases |
WO2012101029A1 (fr) | 2011-01-26 | 2012-08-02 | Nerviano Medical Sciences S.R.L. | Dérivés tricycliques, leur procédé de préparation et leur utilisation à titre d'inhibiteurs de kinases |
WO2012109075A1 (fr) | 2011-02-07 | 2012-08-16 | Plexxikon Inc. | Composés et procédés de modulation de kinase, et leurs indications |
WO2012116217A1 (fr) | 2011-02-25 | 2012-08-30 | Irm Llc | Composés et compositions en tant qu'inhibiteurs de trk |
WO2012113774A1 (fr) | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Dérivés de thiazolylphényl-benzènesulfonamido en tant qu'inhibiteurs de la kinase |
US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
WO2012139930A1 (fr) | 2011-04-11 | 2012-10-18 | Nerviano Medical Sciences S.R.L. | Dérivés pyrazolyl-pyrimidine en tant qu'inhibiteurs des kinases |
US20120271048A1 (en) | 2009-10-27 | 2012-10-25 | Korea Institute Of Science And Technology | Novel 1,6-disubstituted indole compounds as protein kinase inhibitors |
WO2012143248A1 (fr) | 2011-04-19 | 2012-10-26 | Nerviano Medical Sciences S.R.L. | Pyrimidinylpyrroles substitués actifs en tant qu'inhibiteurs de kinases |
US20120277424A1 (en) | 2009-10-22 | 2012-11-01 | Korea Institute Of Science And Technology | 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors |
US20120283261A1 (en) | 2011-04-01 | 2012-11-08 | Bearss David J | Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase |
WO2012152763A1 (fr) | 2011-05-12 | 2012-11-15 | Nerviano Medical Sciences S.R.L. | Dérivés d'indazole substitués actifs en tant qu'inhibiteurs de kinases |
WO2012158413A2 (fr) | 2011-05-13 | 2012-11-22 | Array Biopharma Inc. | Composés de pyrrolidinyle-urée et de pyrrolidinyle thiourée en tant qu'inhibiteurs de kinase trka |
US20120302567A1 (en) | 2010-01-29 | 2012-11-29 | Korea Institute Of Science And Technology | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase |
US8338417B2 (en) | 2007-05-04 | 2012-12-25 | Irm Llc | Compounds and compositions as c-kit and PDGFR kinase inhibitors |
US20130012703A1 (en) | 2009-11-19 | 2013-01-10 | Tae Bo Sim | 2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors |
US8354526B2 (en) | 2008-02-01 | 2013-01-15 | Irm Llc | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors |
WO2013014039A1 (fr) | 2011-07-28 | 2013-01-31 | Nerviano Medical Sciences S.R.L. | Pyrimidinyl-pyrroles substitués alcynyle agissant comme inhibiteurs de kinase |
WO2013016720A2 (fr) | 2011-07-28 | 2013-01-31 | Gerinda Therapeutics, Inc. | Nouveaux dérivés biaryl-hétérocycliques substitués en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer et d'autres maladies |
US20130029925A1 (en) | 2010-02-18 | 2013-01-31 | Universite De Bretagne Occidentale (U.B.O.) | Method for Preventing Cancer Metastasis |
US20130053370A1 (en) | 2010-01-29 | 2013-02-28 | Hanmi Science Co., Ltd. | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES |
WO2013036232A2 (fr) | 2011-09-08 | 2013-03-14 | Deciphera Pharmaceuticals, Llc | Méthodes et compositions pouvant être utilisées en vue du traitement de maladies myéloprolifératives et d'autres maladies prolifératives |
US8399442B2 (en) | 2005-12-30 | 2013-03-19 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2013042137A1 (fr) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Hétérocycles bicycliques convenant comme inhibiteurs de l'irak4 |
WO2013050446A1 (fr) | 2011-10-07 | 2013-04-11 | Nerviano Medical Sciences S.R.L. | Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitués en tant qu'inhibiteurs de kinases |
WO2013050448A1 (fr) | 2011-10-07 | 2013-04-11 | Nerviano Medical Sciences S.R.L. | Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitué par 4-alkyle en tant qu'inhibiteurs de kinases |
WO2013074518A1 (fr) | 2011-11-14 | 2013-05-23 | Tesaro, Inc. | Modulation de certaines tyrosine kinases |
US8461161B2 (en) | 2006-11-15 | 2013-06-11 | Ym Biosciences Australia Pty Ltd | Substituted pyrazines as inhibitors of kinase activity |
WO2013102059A1 (fr) | 2011-12-30 | 2013-07-04 | Pharmacyclics, Inc. | Composés pyrazolo [3, 4-d] pyrimidines et pyrrolo [2, 3-d] pyrimidines en tant qu'inhibiteurs de kinase |
US8501756B2 (en) | 2008-12-09 | 2013-08-06 | Novartis Ag | Heterobicyclic carboxamides as inhibitors for kinases |
US8524709B2 (en) | 2006-09-15 | 2013-09-03 | Tyrogenex, Inc. | Kinase inhibitor compounds |
US8552002B2 (en) | 2004-06-24 | 2013-10-08 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
US8568998B2 (en) | 2004-03-26 | 2013-10-29 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
US20130303518A1 (en) | 2007-05-14 | 2013-11-14 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder |
WO2013174876A1 (fr) | 2012-05-23 | 2013-11-28 | Nerviano Medical Sciences S.R.L. | Procédé de préparation du n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-méthyl-pipérazine-1-yl)-2-(tétrahydro-pyran-4-ylamino)-benzamide |
WO2013183578A1 (fr) | 2012-06-04 | 2013-12-12 | 第一三共株式会社 | DÉRIVÉ D'IMIDAZO[1,2-b]PYRIDAZINE COMME INHIBITEUR DE KINASE |
US8629135B2 (en) | 2008-07-14 | 2014-01-14 | Queen's University At Kingston | Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer |
WO2014011900A2 (fr) | 2012-07-11 | 2014-01-16 | Blueprint Medicines | Inhibiteurs du récepteur du facteur de croissance de fibroblastes |
US8637256B2 (en) | 2005-01-26 | 2014-01-28 | Sphingotec Gmbh | Immunoassay for determining the release of neurotensin into the circulation |
WO2014019908A2 (fr) | 2012-08-02 | 2014-02-06 | Nerviano Medical Sciences S.R.L. | Pyrroles substitués actifs en tant qu'inhibiteurs de kinase |
US8686005B2 (en) | 2006-08-14 | 2014-04-01 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
US20140137274A1 (en) | 2011-11-30 | 2014-05-15 | Lsip, Llc | Induced malignant stem cells |
WO2014075035A1 (fr) | 2012-11-12 | 2014-05-15 | Cephalon, Inc. | Dérivés de bendamustine et leurs procédés d'utilisation |
WO2014072220A1 (fr) | 2012-11-07 | 2014-05-15 | Nerviano Medical Sciences S.R.L. | Pyrimidinyl et pyridinyl-pyrrolopyridinones substitués, procédé pour leur préparation et leur utilisation en tant qu'inhibiteurs de kinases |
WO2014078323A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-pyrrolidinyle, n'-pyrazolyl-urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078372A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-pyrrolidinyle urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078325A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-aryle monocycliques, n'-pyrazolyl-urée, thiourée, guanidine et cyanoguanidine utiles comme inhibiteurs de trka kinase |
WO2014078328A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-pyrrolidinyle, n'-pyrazolyl-urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078322A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de thiazolyl-urée, oxazolyl-urée, thio-urée, guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078331A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-(arylalkyle)-n'-pyrazolyle-urée, de thiourée, de guanidine et de cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078417A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de pyrazolylurée, d'urée, de thiourée, de guanidine et de cyanoguianidine en tant qu'inhibiteurs de la trka kinase |
WO2014078408A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés d'hétéroaryle urée, thiourée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078454A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de thio-urée, guanidine, cynoguanidine et d'urée bicycliques utiles pour le traitement de la douleur |
WO2014078378A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-pyrrolidinyle urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
US8741849B2 (en) | 2007-01-10 | 2014-06-03 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
WO2014083567A2 (fr) | 2012-11-29 | 2014-06-05 | Yeda Research And Development Co. Ltd. | Méthodes de prévention d'une métastase tumorale, de traitement et de pronostic du cancer, et d'identification d'agents susceptibles de constituer des inhibiteurs de métastase |
WO2014086284A1 (fr) | 2012-12-04 | 2014-06-12 | 上海医药集团股份有限公司 | Composé de 3-cyanoquinoléine deutéré, composition pharmaceutique le comprenant, leur procédé de préparation et leur utilisation |
US8754209B2 (en) | 2008-12-05 | 2014-06-17 | Korea Institute Of Science And Technology | Indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient |
US8815901B2 (en) | 2008-05-23 | 2014-08-26 | Novartis Ag | Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors |
US8815906B2 (en) | 2008-03-19 | 2014-08-26 | Chembridge Corporation | Tyrosine kinase inhibitors |
WO2014141187A1 (fr) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property Development Limited | Dérivés pyridine utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret) |
WO2014160521A1 (fr) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Dérivés de pipérazine et leur utilisation comme modulateurs de kit |
WO2014184069A1 (fr) | 2013-05-14 | 2014-11-20 | Nerviano Medical Sciences S.R.L. | Dérivés de 6-amino-7-désaza-purine, procédé pour les préparer et leur utilisation comme inhibiteurs de kinases |
US8895744B2 (en) | 2008-09-08 | 2014-11-25 | Universita' Degli Studi Di Milano-Bicocca | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl |
WO2014194127A1 (fr) | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Composés pour modulation de kinases, et indications correspondantes |
US20140371219A1 (en) | 2011-12-30 | 2014-12-18 | Hanmi Pharm. Co., Ltd | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases |
US8933230B2 (en) | 2011-01-28 | 2015-01-13 | Beijing Konruns Pharmaceutical Co., Ltd. | Phosphorus-containing group-substituted quinoline, its preparation process, medical composition containing the compounds and application |
US8946226B2 (en) | 2008-07-29 | 2015-02-03 | Nerviano Medical Sciences S.R.L. | Use of CDK inhibitor for the treatment of glioma |
WO2015017528A1 (fr) | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Fusions de pik3c2g |
WO2015017533A1 (fr) | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Fusions de ntrk2 |
US20150065468A1 (en) | 2013-08-30 | 2015-03-05 | Ambit Biosciences Corporation | Biaryl acetamide compounds and methods of use thereof |
US20150099762A1 (en) | 2013-03-15 | 2015-04-09 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (ret) inhibitors |
US20150099721A1 (en) | 2012-05-10 | 2015-04-09 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
WO2015057873A1 (fr) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions utiles pour le traitement de troubles associés à l'enzyme kit |
WO2015058129A1 (fr) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Composés à utiliser pour traiter des troubles associés à l'enzyme kit |
WO2015061572A1 (fr) | 2013-10-25 | 2015-04-30 | Blueprint Medicines Corporation | Inhibiteurs du récepteur du facteur de croissance des fibroblastes |
WO2015079251A1 (fr) | 2013-11-29 | 2015-06-04 | Cancer Research Technology Limited | Composés quinazoléine |
WO2015108992A1 (fr) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Composés hétérobicycliques et leur utilisation en tant qu'inhibiteurs du récepteur fgfr4 |
WO2015112806A2 (fr) | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Macrocycles de diaryle en tant que modulateurs de protéines kinases |
US20150238477A1 (en) | 2012-09-07 | 2015-08-27 | Exelixis, Inc. | Method of Treating Lung Adenocarcinoma |
WO2015124697A1 (fr) | 2014-02-20 | 2015-08-27 | Ignyta, Inc. | Composés pour traiter des patients présentant des cellules cancéreuses mutantes ros1 |
US20150272958A1 (en) | 2012-09-25 | 2015-10-01 | Chugai Seiyaku Kabushiki Kaisha | Ret inhibitor |
WO2015161274A1 (fr) | 2014-04-18 | 2015-10-22 | Blueprint Medicines Corporation | Fusions de pik3ca |
WO2015161277A1 (fr) | 2014-04-18 | 2015-10-22 | Blueprint Medicines Corporation | Fusions de met |
US9186318B2 (en) | 2011-09-19 | 2015-11-17 | Beijing Konruns Pharmaceutical Co., Ltd | Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof |
WO2015175788A1 (fr) | 2014-05-15 | 2015-11-19 | Array Biopharma Inc. | 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka |
WO2015191667A1 (fr) | 2014-06-10 | 2015-12-17 | Blueprint Medicines Corporation | Fusions de pkn1 |
WO2015191666A2 (fr) | 2014-06-10 | 2015-12-17 | Blueprint Medicines Corporation | Fusions de raf1 |
US20160000783A1 (en) | 2013-02-19 | 2016-01-07 | Ono Pharmaceutical Co., Ltd. | Trk-INHIBITING COMPOUND |
US20160009709A1 (en) | 2012-12-28 | 2016-01-14 | Oribase Pharma | Protein kinase inhibitors |
WO2016011147A1 (fr) | 2014-07-17 | 2016-01-21 | Blueprint Medicines Corporation | Fusions de prkc |
WO2016011141A1 (fr) | 2014-07-17 | 2016-01-21 | Blueprint Medicines Corporation | Fusions de fgr |
WO2016011144A1 (fr) | 2014-07-17 | 2016-01-21 | Blueprint Medicines Corporation | Hybrides de tert |
US9242977B2 (en) | 2012-04-26 | 2016-01-26 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
WO2016022569A1 (fr) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Composés utiles pour traiter des troubles associés à kit |
US20160046636A1 (en) | 2009-12-29 | 2016-02-18 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
WO2016027754A1 (fr) | 2014-08-18 | 2016-02-25 | 小野薬品工業株式会社 | SEL D'ADDITION ACIDE DE COMPOSÉ INHIBITEUR DE Trk |
WO2016038552A1 (fr) | 2014-09-10 | 2016-03-17 | Glaxosmithkline Intellectual Property Development Limited | Dérivés de pyridone à titre d'inhibiteurs de la kinase réarrangée au cours de la transfection (ret) |
WO2016038519A1 (fr) | 2014-09-08 | 2016-03-17 | Glaxosmithkline Intellectual Property Development Limited | Formes cristallines de 2-(4-(4-éthoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophényl)-n-(5-(1,1,1-trifluoro-2-méthylpropan-2-yl)isoxazol-3-yl)acétamide |
US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US20160137654A1 (en) | 2014-11-16 | 2016-05-19 | Array Biopharma, Inc. | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
WO2016075224A1 (fr) | 2014-11-14 | 2016-05-19 | Nerviano Medical Sciences S.R.L. | Dérivés 6-amino -7-bicyclo -7-déazapurine utiles en tant qu'inhibiteurs de protéine kinase |
WO2016081450A1 (fr) | 2014-11-18 | 2016-05-26 | Blueprint Medicines Corporation | Fusions de prkacb |
WO2016096709A1 (fr) | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Dérivés hétérocycliques modulant l'activité de certaines protéines kinases |
WO2016127074A1 (fr) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | Utilisation de dérivés 2-(pyridine-3-yl)-pyrimidine en tant qu'inhibiteurs de ret |
WO2016137060A1 (fr) | 2015-02-23 | 2016-09-01 | 한양대학교 에리카산학협력단 | Dérivé thiénodiazépine ou sel pharmaceutiquement acceptable de ce dernier, et composition pharmaceutique le contenant en tant que principe actif |
WO2016168992A1 (fr) | 2015-04-21 | 2016-10-27 | Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine | Préparation et utilisation de nouveaux inhibiteurs de protéine kinase |
US9493455B2 (en) | 2012-12-28 | 2016-11-15 | Oribase Pharma | Azaindole derivatives as inhibitors of protein kinases |
US9505784B2 (en) | 2009-06-12 | 2016-11-29 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
US9522910B2 (en) | 2011-06-16 | 2016-12-20 | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon |
WO2017009644A1 (fr) | 2015-07-15 | 2017-01-19 | King's College London | Inhibiteurs de kinases pour une utilisation dans le traitement de la dystrophie facio-scapulo-humérale |
US9550772B2 (en) | 2012-12-28 | 2017-01-24 | Oribase Pharma | Azaindole derivatives as multi kinase inhibitors |
WO2017013160A1 (fr) | 2015-07-21 | 2017-01-26 | Pangaea Biotech, S.L. | Composé 4-amino-6-(2,6-dichlorophényl)-8-méhyle-2-(phénylamino)-pyrido[2,3-d] pyrimidin-7(8h)-one pour le traitement des cancers solides |
WO2017026718A1 (fr) | 2015-08-07 | 2017-02-16 | 한국과학기술연구원 | Nouveau composé 3-(isoxazol-3-yl)-pyrazolo[3,4-d]pyrimidin-4-amine, qui est un inhibiteur de la kinase ret |
US20170044106A1 (en) | 2014-02-14 | 2017-02-16 | Exelixis, Inc. | Crystalline Solid Forms of N--N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, Processes for Making, and Methods of Use |
WO2017027883A1 (fr) | 2015-08-13 | 2017-02-16 | San Diego State University Research Foundation | Atropisomérisme pour une sélectivité accrue des inhibiteurs de kinase |
WO2017043550A1 (fr) | 2015-09-08 | 2017-03-16 | 大鵬薬品工業株式会社 | Composé de pyrimidine condensé ou un sel de celui-ci |
WO2017049462A1 (fr) | 2015-09-22 | 2017-03-30 | 合肥中科普瑞昇生物医药科技有限公司 | Nouvel inhibiteur de la kinase flt3 et ses utilisations |
US20170096425A1 (en) | 2015-07-16 | 2017-04-06 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
US20170114032A1 (en) | 2014-07-17 | 2017-04-27 | Sunshine Lake Pharma Co., Ltd. | Substituted urea derivatives and pharmaceutical uses thereof |
US20170121312A1 (en) | 2015-11-02 | 2017-05-04 | Blueprint Medicines Corporation | Inhibitors of ret |
US9669028B2 (en) | 2011-03-30 | 2017-06-06 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors |
WO2017097697A1 (fr) | 2015-12-08 | 2017-06-15 | Boehringer Ingelheim International Gmbh | Procédé utilisant un gène de fusion ret comme biomarqueur pour sélectionner des patients atteints d'un cancer bronchique non à petites cellules (nsclc) et d'un cancer de la thyroïde pour un traitement anticancéreux |
US20170226100A1 (en) | 2016-02-05 | 2017-08-10 | National Health Research Institutes | Aminothiazole compounds |
US9738660B2 (en) | 2014-10-03 | 2017-08-22 | National Chiao Tung University | Selective inhibitors for protein kinases and pharmaceutical composition and use thereof |
WO2017146116A1 (fr) | 2016-02-23 | 2017-08-31 | 大鵬薬品工業株式会社 | Nouveau composé pyrimidine condensé ou sel de celui-ci |
WO2017145050A1 (fr) | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Dérivé de pyridylpyridone utile comme inhibiteur de la kinase ret dans le traitement du sci et du cancer |
US9758508B2 (en) | 2012-12-28 | 2017-09-12 | Crystalgenomics, Inc. | 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same |
US20170267661A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret |
US20170281632A1 (en) | 2016-04-04 | 2017-10-05 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
WO2017178844A1 (fr) | 2016-04-15 | 2017-10-19 | Cancer Research Technology Limited | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinase ret |
WO2017178845A1 (fr) | 2016-04-15 | 2017-10-19 | Cancer Research Technology Limited | Composés hétérocycliques à utiliser en tant qu'inhibiteurs de kinases ret |
US20170298074A1 (en) | 2014-09-10 | 2017-10-19 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds as rearranged during transfection (ret) inhibitors |
US9801880B2 (en) | 2013-12-02 | 2017-10-31 | Bergenbio As | Use of kinase inhibitors |
-
2018
- 2018-01-18 WO PCT/US2018/014281 patent/WO2018136663A1/fr active Application Filing
Patent Citations (282)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987005297A1 (fr) | 1986-03-03 | 1987-09-11 | The University Of Chicago | Derives de cephalosporines |
US6027927A (en) | 1994-03-18 | 2000-02-22 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5910574A (en) | 1994-03-18 | 1999-06-08 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US6025166A (en) | 1994-03-18 | 2000-02-15 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US6153189A (en) | 1994-03-18 | 2000-11-28 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US6861509B1 (en) | 1996-05-08 | 2005-03-01 | Biogen, Inc. | Antibodies to Ret and RetL3 |
WO1997044356A2 (fr) | 1996-05-08 | 1997-11-27 | Biogen, Inc. | Test diagnostique de detection de la schizophrenie faisant appel a de la miacine |
US20040185547A1 (en) | 1996-08-21 | 2004-09-23 | Sugen, Inc. | Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases |
US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
WO2001016169A2 (fr) | 1999-09-01 | 2001-03-08 | Biogen, Inc. | COMPOSITIONS A BASE DE LIGAND 5 (RetL5) ET SES UTILISATIONS |
WO2001062273A1 (fr) | 2000-02-22 | 2001-08-30 | Hannu Sariola | Utilisation de composes de la famille gdnf pour fabriquer des produits destines au traitement de tumeurs testiculaires |
US7615383B2 (en) | 2000-06-22 | 2009-11-10 | Genentech, Inc. | Methods for treating neuropathy by agonist anti-trk-C monoclonal antibodies |
US7384632B2 (en) | 2000-06-22 | 2008-06-10 | Genentech, Inc. | Agonist anti-trk-C monoclonal antibodies |
WO2003020698A2 (fr) | 2001-09-06 | 2003-03-13 | Prochon Biotech Ltd. | Inhibiteurs de la tyrosine kinase |
US20090130229A1 (en) | 2002-07-23 | 2009-05-21 | Cell Therapeutics, Inc. | Antitumor uses of compound |
US20070265274A1 (en) | 2002-07-24 | 2007-11-15 | Fagin James A | 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases |
US7514446B2 (en) | 2003-02-20 | 2009-04-07 | Smithkline Beecham Corporation | Pyrimidine compounds |
US20090143399A1 (en) | 2003-10-14 | 2009-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
WO2005044835A1 (fr) | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | Procedes de preparation de derives 7-(2'-$g(b)-d-ribofuranosyl substitue)-4-(nr2r3)-5-(ethyn-1-yl substitue)-pyrrolo[2,3-d]pyrimidine |
US20100152219A1 (en) | 2003-11-17 | 2010-06-17 | Astrazeneca R&D | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
US20080262021A1 (en) | 2003-11-21 | 2008-10-23 | Novartis Ag | 1H-Imidazoquinoline Derivatives as Prote In Kinase Inhibitors |
US20080312192A1 (en) | 2003-11-28 | 2008-12-18 | Guido Bold | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases |
US8067434B2 (en) | 2003-12-19 | 2011-11-29 | Plexxikon Inc. | Compounds and methods for development of Ret modulators |
US8106069B2 (en) | 2003-12-24 | 2012-01-31 | Pfizer Italia S.R.L. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them |
US8198298B2 (en) | 2003-12-24 | 2012-06-12 | Pfizer Italia S.R.L. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors |
US20050209195A1 (en) | 2004-01-20 | 2005-09-22 | Cell Therapeutics Europe S.R.I | Indolinone derivatives |
US20090099167A1 (en) | 2004-01-22 | 2009-04-16 | Novartis Institutes For Biomedical Research | Organic compounds |
US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
WO2005070431A1 (fr) | 2004-01-22 | 2005-08-04 | Novartis Ag | Derives de pyrazolo[1,5-a]pyrimidin-7-yl-amine destines a etre utilises dans le traitement de maladies dependantes de la proteine kinase |
US8568998B2 (en) | 2004-03-26 | 2013-10-29 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
US8552002B2 (en) | 2004-06-24 | 2013-10-08 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
US7465726B2 (en) | 2004-08-02 | 2008-12-16 | Osi Pharmaceuticals, Inc. | Substituted pyrrolo[2.3-B]pyridines |
US20080287427A1 (en) | 2004-09-15 | 2008-11-20 | Guido Bold | Bicyclic Amides as Kinase Inhibitors |
US8026247B2 (en) | 2004-09-15 | 2011-09-27 | Novartis Ag | Bicyclic amides as kinase inhibitors |
US20060183900A1 (en) | 2004-10-29 | 2006-08-17 | Shenlin Huang | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
US8637256B2 (en) | 2005-01-26 | 2014-01-28 | Sphingotec Gmbh | Immunoassay for determining the release of neurotensin into the circulation |
US20080234276A1 (en) | 2005-02-01 | 2008-09-25 | Sentinel Oncology Limited | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors |
US20100048540A1 (en) | 2005-02-01 | 2010-02-25 | Sentinel Oncology Limited | Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors |
WO2006089298A2 (fr) | 2005-02-18 | 2006-08-24 | Attenuon, Llc | Derives de diazepine fusionnes pyrimidine et pteridines fusionnees indole |
US20080319005A1 (en) | 2005-04-14 | 2008-12-25 | Guido Bold | Phenylacetamides Suitable as Protein Kinase Inhibitors |
US20090215761A1 (en) | 2005-04-15 | 2009-08-27 | Cylene Pharmaceuticals, Inc. | Quinobenzoxazine analogs and methods of using thereof |
WO2006123113A2 (fr) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Composes chimiques |
US8114989B2 (en) | 2005-05-16 | 2012-02-14 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
US20090048249A1 (en) | 2005-05-31 | 2009-02-19 | George Chiu | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
WO2006130613A2 (fr) | 2005-05-31 | 2006-12-07 | The Pfahl Family Trust (Dated 9 July 1996) | Derives de biarylheterocycle substitues utilises comme inhibiteurs de la proteine kinase pour le traitement du cancer et d'autres maladies |
US8691221B2 (en) | 2005-06-07 | 2014-04-08 | Lay Line Genomics S.P.A. | Analgesic treatment with prolonged effect |
WO2006131952A1 (fr) | 2005-06-07 | 2006-12-14 | Lay Line Genomics S.P.A. | Traitement analgesique a effet prolonge |
WO2007002433A1 (fr) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Derives de pyrrolo [2, 3-b] pyridine utilises comme inhibiteurs de proteines kinases |
WO2007002325A1 (fr) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Composes et methodes de modulation de la kinase et instructions afferentes |
US20160176865A1 (en) | 2005-06-22 | 2016-06-23 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US7863288B2 (en) | 2005-06-22 | 2011-01-04 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20080234284A1 (en) | 2005-07-21 | 2008-09-25 | Patricia Imbach | Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors |
US8673347B2 (en) | 2005-08-25 | 2014-03-18 | Creabilis Therapeutics S.P.A. | Polymer conjugates of K-252A and derivatives thereof |
WO2007022999A1 (fr) | 2005-08-25 | 2007-03-01 | Creabilis Therapeutics S.P.A. | Conjugues polymeres de k-252a et leurs derives |
US20070117800A1 (en) | 2005-11-03 | 2007-05-24 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
US20070149523A1 (en) | 2005-11-14 | 2007-06-28 | Jan Ehlert | Thiazole Analogues and Uses Thereof |
WO2007054357A1 (fr) | 2005-11-14 | 2007-05-18 | 4Sc Ag | Analogues de thiazole et leurs utilisations |
WO2007057397A1 (fr) | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Traitement du cancer |
WO2007057399A2 (fr) | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Traitement du cancer |
US20080275054A1 (en) | 2005-11-30 | 2008-11-06 | Philipp Holzer | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors |
US7795273B2 (en) | 2005-12-08 | 2010-09-14 | Novartis Ag | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors |
US8399442B2 (en) | 2005-12-30 | 2013-03-19 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2007087245A2 (fr) | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Inhibition de la tyrosine kinase ret |
US20100004239A1 (en) | 2006-01-27 | 2010-01-07 | Peng Cho Tang | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors |
WO2007109045A1 (fr) | 2006-03-16 | 2007-09-27 | Novartis Ag | composes organiques |
US20090069360A1 (en) | 2006-03-16 | 2009-03-12 | David Bryant Batt | Organic Compounds |
US8129374B2 (en) | 2006-03-17 | 2012-03-06 | Ambit Bioscience Corporation | Method of using imidazolothiazole compounds for the treatment of disease |
WO2007110344A1 (fr) | 2006-03-27 | 2007-10-04 | Nerviano Medical Sciences S.R.L. | Dérivés de pyrrole, de thiophène et de furane substitués par un pyridyle et dérivés de pyrrole, de thiophène et de furane substitués par un pyrimidinyle en tant qu'inhibiteurs de kinase |
US20090312321A1 (en) | 2006-05-15 | 2009-12-17 | Irm Llc | Compositions and methods for fgf receptor kinases inhibitors |
US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
US8686005B2 (en) | 2006-08-14 | 2014-04-01 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
US20110195072A1 (en) | 2006-09-12 | 2011-08-11 | Anne Boulay | Non-neuroendocrine cancer therapy |
US8524709B2 (en) | 2006-09-15 | 2013-09-03 | Tyrogenex, Inc. | Kinase inhibitor compounds |
US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
US20100069395A1 (en) | 2006-10-30 | 2010-03-18 | Patricia Imbach | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors |
US8461161B2 (en) | 2006-11-15 | 2013-06-11 | Ym Biosciences Australia Pty Ltd | Substituted pyrazines as inhibitors of kinase activity |
WO2008079906A1 (fr) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Composés et méthodes pour moduler une kinase et indications associées |
WO2008080001A2 (fr) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Composés et procédés pour la modulation de kinases et indications pour celle-ci |
WO2008079903A1 (fr) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Dérivés de pyrrolo [2, 3-b] pyridine utilisés comme modulateurs de kinase |
WO2008079909A1 (fr) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Composés et méthodes de modulation des kinases, et indications connexes |
WO2008080015A2 (fr) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Composés et procédés pour la modulation des kinases, et indications correspondantes |
US7863289B2 (en) | 2006-12-21 | 2011-01-04 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8741849B2 (en) | 2007-01-10 | 2014-06-03 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
US20080199426A1 (en) | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
US20100173954A1 (en) | 2007-01-19 | 2010-07-08 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
US20110053934A1 (en) | 2007-03-20 | 2011-03-03 | Glaxosmithkline Llc | Compounds and methods of treatment |
US20080234267A1 (en) | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
US20110189167A1 (en) | 2007-04-20 | 2011-08-04 | Flynn Daniel L | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases |
US8338417B2 (en) | 2007-05-04 | 2012-12-25 | Irm Llc | Compounds and compositions as c-kit and PDGFR kinase inhibitors |
US20130303518A1 (en) | 2007-05-14 | 2013-11-14 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder |
US20090012045A1 (en) | 2007-06-26 | 2009-01-08 | Rigel Pharmaceuticals, Inc. | Methods of Treating Cell Proliferative Disorders |
WO2009007748A2 (fr) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Composés 945 |
US20100209488A1 (en) | 2007-07-16 | 2010-08-19 | The Regents Of The University Of California | Protein kinase modulating compounds and methods for making and using them |
WO2009012283A1 (fr) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Composés et procédés pour la modulation des kinases et leurs indications |
WO2009013126A1 (fr) | 2007-07-20 | 2009-01-29 | Nerviano Medical Sciences S.R.L. | Dérivés d'indazole substitués actifs comme inhibiteurs de kinases |
US8299057B2 (en) | 2007-07-20 | 2012-10-30 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
WO2009017838A2 (fr) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinaisons d'inhibiteurs jak-2 et d'autres agents |
WO2009023978A1 (fr) | 2007-08-17 | 2009-02-26 | Oncalis Ag | Composés pyrazolo[3,4-d]pyrimidines et leur utilisation en tant que modulateurs de protéine kinase |
WO2009042646A1 (fr) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Agents antiprolifératifs |
US20100297115A1 (en) | 2007-10-23 | 2010-11-25 | Novartis Ag | Use of trkb antibodies for the treatment of respiratory disorders |
WO2009053442A1 (fr) | 2007-10-23 | 2009-04-30 | Novartis Ag | Utilisation d'anticorps trkb pour le traitement de troubles respiratoires |
WO2009071480A2 (fr) | 2007-12-04 | 2009-06-11 | Nerviano Medical Sciences S.R.L. | Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase |
WO2009092049A1 (fr) | 2008-01-17 | 2009-07-23 | Irm Llc | Anticorps anti-trkb améliorés |
US8642035B2 (en) | 2008-01-17 | 2014-02-04 | Irm Llc | Anti-TrkB antibodies |
US20090227556A1 (en) | 2008-01-31 | 2009-09-10 | Eisai R&D Management Co., Ltd. | Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives |
US8354526B2 (en) | 2008-02-01 | 2013-01-15 | Irm Llc | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors |
US20090209496A1 (en) | 2008-02-15 | 2009-08-20 | David Chaplin | Methods and compositions for enhancing the efficacy of rtk inhibitors |
US20120065233A1 (en) | 2008-03-19 | 2012-03-15 | Vlad Edward Gregor | Tyrosine kinase inhibitors |
US8815906B2 (en) | 2008-03-19 | 2014-08-26 | Chembridge Corporation | Tyrosine kinase inhibitors |
WO2009118411A2 (fr) | 2008-03-28 | 2009-10-01 | Nerviano Medical Sciences S.R.L. | Dérivés actifs de 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one en tant qu’inhibiteurs de kinase, procédé pour leur préparation et compositions pharmaceutiques les contenant |
US9260437B2 (en) | 2008-05-19 | 2016-02-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8912204B2 (en) | 2008-05-19 | 2014-12-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009143024A2 (fr) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Composés et procédés de modulation des kinases, et indications associées |
WO2009143018A2 (fr) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Composés et procédés de modulation des kinases, et indications associées |
US8815901B2 (en) | 2008-05-23 | 2014-08-26 | Novartis Ag | Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors |
US20110212053A1 (en) | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
US8629135B2 (en) | 2008-07-14 | 2014-01-14 | Queen's University At Kingston | Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer |
US8946226B2 (en) | 2008-07-29 | 2015-02-03 | Nerviano Medical Sciences S.R.L. | Use of CDK inhibitor for the treatment of glioma |
US20100075916A1 (en) | 2008-09-05 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases |
US8895744B2 (en) | 2008-09-08 | 2014-11-25 | Universita' Degli Studi Di Milano-Bicocca | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl |
WO2010031816A1 (fr) | 2008-09-19 | 2010-03-25 | Nerviano Medical Sciences S.R.L. | Dérivés de 3,4-dihydro-2h-pyrrolo[1,2-a]pyrazine-1-one |
WO2010033941A1 (fr) | 2008-09-22 | 2010-03-25 | Array Biopharma Inc. | Composés imidazo[1,2b]pyridazine substitués comme inhibiteurs de kinases trk |
US8450322B2 (en) | 2008-09-22 | 2013-05-28 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors |
US20100081675A1 (en) | 2008-09-26 | 2010-04-01 | National Health Research Institutes | Fused multicyclic compounds as protein kinase inhibitors |
US8513263B2 (en) | 2008-10-22 | 2013-08-20 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
WO2010048314A1 (fr) | 2008-10-22 | 2010-04-29 | Array Biopharma Inc. | Composés de pyrazolo[1,5-a]pyrimidine substitués comme inhibiteurs de la trk kinase |
US20120070410A1 (en) | 2008-11-06 | 2012-03-22 | Apuy Julius L | Imidazolothiazole compounds and methods of use thereof |
US8912194B2 (en) | 2008-11-24 | 2014-12-16 | Nerviano Medical Sciences S.R.L. | CDK inhibitor for the treatment of mesothelioma |
WO2010058006A1 (fr) | 2008-11-24 | 2010-05-27 | Nerviano Medical Sciences S.R.L. | Inhibiteur de cdk (kinase cycline-dépendante) pour le traitement d'un mésothéliome |
US8754209B2 (en) | 2008-12-05 | 2014-06-17 | Korea Institute Of Science And Technology | Indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient |
US8501756B2 (en) | 2008-12-09 | 2013-08-06 | Novartis Ag | Heterobicyclic carboxamides as inhibitors for kinases |
WO2010111527A1 (fr) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines en tant qu'inhibiteurs de la kinase et leur utilisation médicale |
US20100280012A1 (en) | 2009-04-29 | 2010-11-04 | Industrial Technology Research Institute | Azaazulene compounds |
US9505784B2 (en) | 2009-06-12 | 2016-11-29 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
WO2010145998A1 (fr) | 2009-06-15 | 2010-12-23 | Nerviano Medical Sciences S.R.L. | Dérivés de pyrimidinylpyrrolopyridinone substitués, procédé pour leur préparation et leur utilisation en tant qu'inhibiteurs de kinase |
US8791123B2 (en) | 2009-07-09 | 2014-07-29 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
WO2011006074A1 (fr) | 2009-07-09 | 2011-01-13 | Array Biopharma Inc. | Composés pyrazolo[1,5-a]pyrimidines substituées en tant qu'inhibiteurs des trk kinases |
US20110046370A1 (en) | 2009-08-20 | 2011-02-24 | Korea Institute Of Science And Technology | 1,3,6-substituted indole derivatives having inhibitory activity for protein kinase |
US20130079343A1 (en) | 2009-08-20 | 2013-03-28 | Korea Institute Of Science And Technology | 1,3,6-Substituted Indole Derivatives Having Inhibitory Activity for Protein Kinase |
US20120277424A1 (en) | 2009-10-22 | 2012-11-01 | Korea Institute Of Science And Technology | 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors |
US20120271048A1 (en) | 2009-10-27 | 2012-10-25 | Korea Institute Of Science And Technology | Novel 1,6-disubstituted indole compounds as protein kinase inhibitors |
US20110269739A1 (en) | 2009-10-29 | 2011-11-03 | Oscotec, Inc. | Kinase inhibitors |
US20110281841A1 (en) | 2009-11-13 | 2011-11-17 | Oscotec, Inc. | Kinase Inhibitors |
US20130012703A1 (en) | 2009-11-19 | 2013-01-10 | Tae Bo Sim | 2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors |
US20160046636A1 (en) | 2009-12-29 | 2016-02-18 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
US20120302567A1 (en) | 2010-01-29 | 2012-11-29 | Korea Institute Of Science And Technology | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase |
WO2011092120A1 (fr) | 2010-01-29 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | Dérivés de 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one comme modulateurs de protéines kinases |
US20130053370A1 (en) | 2010-01-29 | 2013-02-28 | Hanmi Science Co., Ltd. | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES |
US20130029925A1 (en) | 2010-02-18 | 2013-01-31 | Universite De Bretagne Occidentale (U.B.O.) | Method for Preventing Cancer Metastasis |
WO2011133637A2 (fr) | 2010-04-21 | 2011-10-27 | Plexxikon, Inc. | Compositions et méthodes de modulation des kinases et leurs indications |
US8933084B2 (en) | 2010-05-20 | 2015-01-13 | Array Biopharma Inc. | Macrocyclic compounds as Trk kinase inhibitors |
WO2011146336A1 (fr) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Composés macrocycliques en tant qu'inhibiteurs de kinase trk |
WO2012034095A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions comme inhibiteurs de trk |
WO2012034091A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions à titre d'inhibiteurs de trk |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012047017A2 (fr) | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant |
WO2012053606A1 (fr) | 2010-10-22 | 2012-04-26 | アステラス製薬株式会社 | Carboxamide arylaminohétérocyclique |
WO2012101029A1 (fr) | 2011-01-26 | 2012-08-02 | Nerviano Medical Sciences S.R.L. | Dérivés tricycliques, leur procédé de préparation et leur utilisation à titre d'inhibiteurs de kinases |
WO2012101032A1 (fr) | 2011-01-26 | 2012-08-02 | Nerviano Medical Sciences S.R.L. | Dérivés pyrrolo tricycliques, leur procédé de préparation et leur utilisation à titre d'inhibiteurs de kinases |
US8933230B2 (en) | 2011-01-28 | 2015-01-13 | Beijing Konruns Pharmaceutical Co., Ltd. | Phosphorus-containing group-substituted quinoline, its preparation process, medical composition containing the compounds and application |
WO2012109075A1 (fr) | 2011-02-07 | 2012-08-16 | Plexxikon Inc. | Composés et procédés de modulation de kinase, et leurs indications |
WO2012113774A1 (fr) | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Dérivés de thiazolylphényl-benzènesulfonamido en tant qu'inhibiteurs de la kinase |
US9102671B2 (en) | 2011-02-25 | 2015-08-11 | Novartis Ag | Compounds and compositions as TRK inhibitors |
WO2012116217A1 (fr) | 2011-02-25 | 2012-08-30 | Irm Llc | Composés et compositions en tant qu'inhibiteurs de trk |
US9669028B2 (en) | 2011-03-30 | 2017-06-06 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors |
US20120283261A1 (en) | 2011-04-01 | 2012-11-08 | Bearss David J | Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase |
WO2012139930A1 (fr) | 2011-04-11 | 2012-10-18 | Nerviano Medical Sciences S.R.L. | Dérivés pyrazolyl-pyrimidine en tant qu'inhibiteurs des kinases |
WO2012143248A1 (fr) | 2011-04-19 | 2012-10-26 | Nerviano Medical Sciences S.R.L. | Pyrimidinylpyrroles substitués actifs en tant qu'inhibiteurs de kinases |
WO2012152763A1 (fr) | 2011-05-12 | 2012-11-15 | Nerviano Medical Sciences S.R.L. | Dérivés d'indazole substitués actifs en tant qu'inhibiteurs de kinases |
US20150166564A1 (en) | 2011-05-13 | 2015-06-18 | Array BioPharama Inc. | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors |
WO2012158413A2 (fr) | 2011-05-13 | 2012-11-22 | Array Biopharma Inc. | Composés de pyrrolidinyle-urée et de pyrrolidinyle thiourée en tant qu'inhibiteurs de kinase trka |
US9522910B2 (en) | 2011-06-16 | 2016-12-20 | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon |
WO2013016720A2 (fr) | 2011-07-28 | 2013-01-31 | Gerinda Therapeutics, Inc. | Nouveaux dérivés biaryl-hétérocycliques substitués en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer et d'autres maladies |
WO2013014039A1 (fr) | 2011-07-28 | 2013-01-31 | Nerviano Medical Sciences S.R.L. | Pyrimidinyl-pyrroles substitués alcynyle agissant comme inhibiteurs de kinase |
US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
WO2013036232A2 (fr) | 2011-09-08 | 2013-03-14 | Deciphera Pharmaceuticals, Llc | Méthodes et compositions pouvant être utilisées en vue du traitement de maladies myéloprolifératives et d'autres maladies prolifératives |
US9186318B2 (en) | 2011-09-19 | 2015-11-17 | Beijing Konruns Pharmaceutical Co., Ltd | Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof |
WO2013042137A1 (fr) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Hétérocycles bicycliques convenant comme inhibiteurs de l'irak4 |
WO2013050446A1 (fr) | 2011-10-07 | 2013-04-11 | Nerviano Medical Sciences S.R.L. | Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitués en tant qu'inhibiteurs de kinases |
WO2013050448A1 (fr) | 2011-10-07 | 2013-04-11 | Nerviano Medical Sciences S.R.L. | Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitué par 4-alkyle en tant qu'inhibiteurs de kinases |
WO2013074518A1 (fr) | 2011-11-14 | 2013-05-23 | Tesaro, Inc. | Modulation de certaines tyrosine kinases |
US20150306086A1 (en) | 2011-11-14 | 2015-10-29 | Tesaro, Inc. | Modulating certain tyrosine kinases |
US20140137274A1 (en) | 2011-11-30 | 2014-05-15 | Lsip, Llc | Induced malignant stem cells |
WO2013102059A1 (fr) | 2011-12-30 | 2013-07-04 | Pharmacyclics, Inc. | Composés pyrazolo [3, 4-d] pyrimidines et pyrrolo [2, 3-d] pyrimidines en tant qu'inhibiteurs de kinase |
US20140371219A1 (en) | 2011-12-30 | 2014-12-18 | Hanmi Pharm. Co., Ltd | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases |
US9273051B2 (en) | 2011-12-30 | 2016-03-01 | Pharmacyclics Llc | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US20150018336A1 (en) | 2011-12-30 | 2015-01-15 | Pharmacyclics, Inc. | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRAZOLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS |
US9242977B2 (en) | 2012-04-26 | 2016-01-26 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
US20150099721A1 (en) | 2012-05-10 | 2015-04-09 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
WO2013174876A1 (fr) | 2012-05-23 | 2013-11-28 | Nerviano Medical Sciences S.R.L. | Procédé de préparation du n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-méthyl-pipérazine-1-yl)-2-(tétrahydro-pyran-4-ylamino)-benzamide |
US20150051222A1 (en) | 2012-05-23 | 2015-02-19 | Nerviano Medical Sciences S.R.L. | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
WO2013183578A1 (fr) | 2012-06-04 | 2013-12-12 | 第一三共株式会社 | DÉRIVÉ D'IMIDAZO[1,2-b]PYRIDAZINE COMME INHIBITEUR DE KINASE |
WO2014011900A2 (fr) | 2012-07-11 | 2014-01-16 | Blueprint Medicines | Inhibiteurs du récepteur du facteur de croissance de fibroblastes |
WO2014019908A2 (fr) | 2012-08-02 | 2014-02-06 | Nerviano Medical Sciences S.R.L. | Pyrroles substitués actifs en tant qu'inhibiteurs de kinase |
US20150238477A1 (en) | 2012-09-07 | 2015-08-27 | Exelixis, Inc. | Method of Treating Lung Adenocarcinoma |
US20150272958A1 (en) | 2012-09-25 | 2015-10-01 | Chugai Seiyaku Kabushiki Kaisha | Ret inhibitor |
WO2014072220A1 (fr) | 2012-11-07 | 2014-05-15 | Nerviano Medical Sciences S.R.L. | Pyrimidinyl et pyridinyl-pyrrolopyridinones substitués, procédé pour leur préparation et leur utilisation en tant qu'inhibiteurs de kinases |
US9604980B2 (en) | 2012-11-07 | 2017-03-28 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors |
WO2014075035A1 (fr) | 2012-11-12 | 2014-05-15 | Cephalon, Inc. | Dérivés de bendamustine et leurs procédés d'utilisation |
US9149464B2 (en) | 2012-11-12 | 2015-10-06 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
US9150517B2 (en) | 2012-11-12 | 2015-10-06 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
WO2014078323A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-pyrrolidinyle, n'-pyrazolyl-urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078328A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-pyrrolidinyle, n'-pyrazolyl-urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078408A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés d'hétéroaryle urée, thiourée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078322A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de thiazolyl-urée, oxazolyl-urée, thio-urée, guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078372A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-pyrrolidinyle urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078378A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-pyrrolidinyle urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078454A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de thio-urée, guanidine, cynoguanidine et d'urée bicycliques utiles pour le traitement de la douleur |
WO2014078325A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-aryle monocycliques, n'-pyrazolyl-urée, thiourée, guanidine et cyanoguanidine utiles comme inhibiteurs de trka kinase |
WO2014078331A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-(arylalkyle)-n'-pyrazolyle-urée, de thiourée, de guanidine et de cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
WO2014078417A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de pyrazolylurée, d'urée, de thiourée, de guanidine et de cyanoguianidine en tant qu'inhibiteurs de la trka kinase |
WO2014083567A2 (fr) | 2012-11-29 | 2014-06-05 | Yeda Research And Development Co. Ltd. | Méthodes de prévention d'une métastase tumorale, de traitement et de pronostic du cancer, et d'identification d'agents susceptibles de constituer des inhibiteurs de métastase |
WO2014086284A1 (fr) | 2012-12-04 | 2014-06-12 | 上海医药集团股份有限公司 | Composé de 3-cyanoquinoléine deutéré, composition pharmaceutique le comprenant, leur procédé de préparation et leur utilisation |
US9758508B2 (en) | 2012-12-28 | 2017-09-12 | Crystalgenomics, Inc. | 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same |
US9493455B2 (en) | 2012-12-28 | 2016-11-15 | Oribase Pharma | Azaindole derivatives as inhibitors of protein kinases |
US9550772B2 (en) | 2012-12-28 | 2017-01-24 | Oribase Pharma | Azaindole derivatives as multi kinase inhibitors |
US20160009709A1 (en) | 2012-12-28 | 2016-01-14 | Oribase Pharma | Protein kinase inhibitors |
US20160000783A1 (en) | 2013-02-19 | 2016-01-07 | Ono Pharmaceutical Co., Ltd. | Trk-INHIBITING COMPOUND |
WO2014141187A1 (fr) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property Development Limited | Dérivés pyridine utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret) |
WO2014160521A1 (fr) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Dérivés de pipérazine et leur utilisation comme modulateurs de kit |
US20150099762A1 (en) | 2013-03-15 | 2015-04-09 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (ret) inhibitors |
US9789100B2 (en) | 2013-03-15 | 2017-10-17 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
WO2014184069A1 (fr) | 2013-05-14 | 2014-11-20 | Nerviano Medical Sciences S.R.L. | Dérivés de 6-amino-7-désaza-purine, procédé pour les préparer et leur utilisation comme inhibiteurs de kinases |
US9682083B2 (en) | 2013-05-14 | 2017-06-20 | Nerviano Medical Sciences S.R.L. | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
WO2014194127A1 (fr) | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Composés pour modulation de kinases, et indications correspondantes |
WO2015017528A1 (fr) | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Fusions de pik3c2g |
WO2015017533A1 (fr) | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Fusions de ntrk2 |
US20150065468A1 (en) | 2013-08-30 | 2015-03-05 | Ambit Biosciences Corporation | Biaryl acetamide compounds and methods of use thereof |
WO2015058129A1 (fr) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Composés à utiliser pour traiter des troubles associés à l'enzyme kit |
WO2015057873A1 (fr) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions utiles pour le traitement de troubles associés à l'enzyme kit |
WO2015061572A1 (fr) | 2013-10-25 | 2015-04-30 | Blueprint Medicines Corporation | Inhibiteurs du récepteur du facteur de croissance des fibroblastes |
WO2015079251A1 (fr) | 2013-11-29 | 2015-06-04 | Cancer Research Technology Limited | Composés quinazoléine |
US9801880B2 (en) | 2013-12-02 | 2017-10-31 | Bergenbio As | Use of kinase inhibitors |
WO2015108992A1 (fr) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Composés hétérobicycliques et leur utilisation en tant qu'inhibiteurs du récepteur fgfr4 |
WO2015112806A2 (fr) | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Macrocycles de diaryle en tant que modulateurs de protéines kinases |
US20170044106A1 (en) | 2014-02-14 | 2017-02-16 | Exelixis, Inc. | Crystalline Solid Forms of N--N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, Processes for Making, and Methods of Use |
WO2015124697A1 (fr) | 2014-02-20 | 2015-08-27 | Ignyta, Inc. | Composés pour traiter des patients présentant des cellules cancéreuses mutantes ros1 |
US20150283132A1 (en) | 2014-02-20 | 2015-10-08 | Ignyta, Inc. | Molecules for administration to ros1 mutant cancer cells |
WO2015161277A1 (fr) | 2014-04-18 | 2015-10-22 | Blueprint Medicines Corporation | Fusions de met |
WO2015161274A1 (fr) | 2014-04-18 | 2015-10-22 | Blueprint Medicines Corporation | Fusions de pik3ca |
WO2015175788A1 (fr) | 2014-05-15 | 2015-11-19 | Array Biopharma Inc. | 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka |
WO2015191666A2 (fr) | 2014-06-10 | 2015-12-17 | Blueprint Medicines Corporation | Fusions de raf1 |
WO2015191667A1 (fr) | 2014-06-10 | 2015-12-17 | Blueprint Medicines Corporation | Fusions de pkn1 |
WO2016011141A1 (fr) | 2014-07-17 | 2016-01-21 | Blueprint Medicines Corporation | Fusions de fgr |
WO2016011147A1 (fr) | 2014-07-17 | 2016-01-21 | Blueprint Medicines Corporation | Fusions de prkc |
US20170114032A1 (en) | 2014-07-17 | 2017-04-27 | Sunshine Lake Pharma Co., Ltd. | Substituted urea derivatives and pharmaceutical uses thereof |
WO2016011144A1 (fr) | 2014-07-17 | 2016-01-21 | Blueprint Medicines Corporation | Hybrides de tert |
WO2016022569A1 (fr) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Composés utiles pour traiter des troubles associés à kit |
WO2016027754A1 (fr) | 2014-08-18 | 2016-02-25 | 小野薬品工業株式会社 | SEL D'ADDITION ACIDE DE COMPOSÉ INHIBITEUR DE Trk |
US20170283404A1 (en) | 2014-09-08 | 2017-10-05 | Glaxosmithkline Intellectual Property Development Limited | Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide |
WO2016038519A1 (fr) | 2014-09-08 | 2016-03-17 | Glaxosmithkline Intellectual Property Development Limited | Formes cristallines de 2-(4-(4-éthoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophényl)-n-(5-(1,1,1-trifluoro-2-méthylpropan-2-yl)isoxazol-3-yl)acétamide |
WO2016038552A1 (fr) | 2014-09-10 | 2016-03-17 | Glaxosmithkline Intellectual Property Development Limited | Dérivés de pyridone à titre d'inhibiteurs de la kinase réarrangée au cours de la transfection (ret) |
US20170298074A1 (en) | 2014-09-10 | 2017-10-19 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds as rearranged during transfection (ret) inhibitors |
US9738660B2 (en) | 2014-10-03 | 2017-08-22 | National Chiao Tung University | Selective inhibitors for protein kinases and pharmaceutical composition and use thereof |
WO2016075224A1 (fr) | 2014-11-14 | 2016-05-19 | Nerviano Medical Sciences S.R.L. | Dérivés 6-amino -7-bicyclo -7-déazapurine utiles en tant qu'inhibiteurs de protéine kinase |
US20160137654A1 (en) | 2014-11-16 | 2016-05-19 | Array Biopharma, Inc. | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
WO2016077841A1 (fr) | 2014-11-16 | 2016-05-19 | Array Biopharma, Inc. | Forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
WO2016081450A1 (fr) | 2014-11-18 | 2016-05-26 | Blueprint Medicines Corporation | Fusions de prkacb |
WO2016096709A1 (fr) | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Dérivés hétérocycliques modulant l'activité de certaines protéines kinases |
WO2016127074A1 (fr) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | Utilisation de dérivés 2-(pyridine-3-yl)-pyrimidine en tant qu'inhibiteurs de ret |
WO2016137060A1 (fr) | 2015-02-23 | 2016-09-01 | 한양대학교 에리카산학협력단 | Dérivé thiénodiazépine ou sel pharmaceutiquement acceptable de ce dernier, et composition pharmaceutique le contenant en tant que principe actif |
WO2016168992A1 (fr) | 2015-04-21 | 2016-10-27 | Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine | Préparation et utilisation de nouveaux inhibiteurs de protéine kinase |
WO2017009644A1 (fr) | 2015-07-15 | 2017-01-19 | King's College London | Inhibiteurs de kinases pour une utilisation dans le traitement de la dystrophie facio-scapulo-humérale |
US20170096425A1 (en) | 2015-07-16 | 2017-04-06 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2017013160A1 (fr) | 2015-07-21 | 2017-01-26 | Pangaea Biotech, S.L. | Composé 4-amino-6-(2,6-dichlorophényl)-8-méhyle-2-(phénylamino)-pyrido[2,3-d] pyrimidin-7(8h)-one pour le traitement des cancers solides |
WO2017026718A1 (fr) | 2015-08-07 | 2017-02-16 | 한국과학기술연구원 | Nouveau composé 3-(isoxazol-3-yl)-pyrazolo[3,4-d]pyrimidin-4-amine, qui est un inhibiteur de la kinase ret |
WO2017027883A1 (fr) | 2015-08-13 | 2017-02-16 | San Diego State University Research Foundation | Atropisomérisme pour une sélectivité accrue des inhibiteurs de kinase |
US20180009817A1 (en) | 2015-09-08 | 2018-01-11 | Taiho Pharmaceutical Co., Ltd. | Fused pyrimidine compound or salt thereof |
WO2017043550A1 (fr) | 2015-09-08 | 2017-03-16 | 大鵬薬品工業株式会社 | Composé de pyrimidine condensé ou un sel de celui-ci |
WO2017049462A1 (fr) | 2015-09-22 | 2017-03-30 | 合肥中科普瑞昇生物医药科技有限公司 | Nouvel inhibiteur de la kinase flt3 et ses utilisations |
US20170121312A1 (en) | 2015-11-02 | 2017-05-04 | Blueprint Medicines Corporation | Inhibitors of ret |
WO2017097697A1 (fr) | 2015-12-08 | 2017-06-15 | Boehringer Ingelheim International Gmbh | Procédé utilisant un gène de fusion ret comme biomarqueur pour sélectionner des patients atteints d'un cancer bronchique non à petites cellules (nsclc) et d'un cancer de la thyroïde pour un traitement anticancéreux |
US20170226100A1 (en) | 2016-02-05 | 2017-08-10 | National Health Research Institutes | Aminothiazole compounds |
WO2017145050A1 (fr) | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Dérivé de pyridylpyridone utile comme inhibiteur de la kinase ret dans le traitement du sci et du cancer |
WO2017146116A1 (fr) | 2016-02-23 | 2017-08-31 | 大鵬薬品工業株式会社 | Nouveau composé pyrimidine condensé ou sel de celui-ci |
US20180009818A1 (en) | 2016-02-23 | 2018-01-11 | Taiho Pharmaceutical Co., Ltd. | Novel fused pyrimidine compound or salt thereof |
US20170267661A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret |
US20170281632A1 (en) | 2016-04-04 | 2017-10-05 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
WO2017178844A1 (fr) | 2016-04-15 | 2017-10-19 | Cancer Research Technology Limited | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinase ret |
WO2017178845A1 (fr) | 2016-04-15 | 2017-10-19 | Cancer Research Technology Limited | Composés hétérocycliques à utiliser en tant qu'inhibiteurs de kinases ret |
Non-Patent Citations (100)
Title |
---|
"Cancer Genome Atlas Network", NATURE, vol. 487, 2012, pages 330 - 337 |
ACS MED. CHEM. LETT., vol. 6, no. 5, 2015, pages 562 - 567 |
ACSMED. CHEM. LETT., vol. 3, no. 2, 2012, pages 140 - 145 |
ACTA DERM. VENEREOL., vol. 95, 2015, pages 542 - 548 |
AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, 1 April 2017 (2017-04-01) |
AMIT M ET AL., ONCOGENE, vol. 36, 8 June 2017 (2017-06-08), pages 3232 - 3239 |
ANDREUCCI ET AL., ONCOTARGET, vol. 7, 2017, pages 80543 - 80553 |
ARIGHI ET AL., CYTOKINE GROWTH FACTOR REV., vol. 16, 2005, pages 441 - 67 |
AVERY MD; FIRST LR: "Pediatric Medicine", 1994, WILLIAMS & WILKINS |
BALLERINI, P. ET AL., LEUKEMIA, vol. 26, 2012, pages 2384 - 2389 |
BERHMAN RE; KLIEGMAN R; ARVIN AM; NELSON WE: "Nelson Textbook of Pediatrics", 1996, W.B. SAUNDERS COMPANY |
BHINGE ET AL., ONCOTARGET, vol. 8, 2017, pages 27155 - 27165 |
BORRELLO, M.G. ET AL., EXPERT OPIN. THER. TARGETS, vol. 17, no. 4, 2013, pages 403 - 419 |
BOULAY ET AL., CANCER RES., vol. 68, 2008, pages 3743 - 51 |
BRODEUR, G. M., NATURE REF. CANCER, vol. 3, 2003, pages 203 - 216 |
BUTLER TJADEN N. ET AL., TRANSL. RES., vol. 162, 2013, pages 1 - 15 |
CAMILLERI, M., N. ENGL. J. MED., vol. 367, 2012, pages 1626 - 1635 |
CAMOS, M., CANCER RES., vol. 66, 2006, pages 6947 - 6954 |
CANCER BIOL. THER., vol. 16, no. 3, 2015, pages 477 - 483 |
CANCER CHEMOTHER. PHARMACOL., vol. 70, 2012, pages 477 - 486 |
CANCER CHEMOTHER. PHARMACOL., vol. 75, no. 1, 2015, pages 131 - 141 |
CANCER, vol. 117, no. 6, 2011, pages 1321 - 1391 |
CHANG ET AL., YONSEI MED. J., vol. 58, 2017, pages 9 - 18 |
DAWSON, D. M., J NATL CANCER INST, vol. 90, 1998, pages 519 - 523 |
DE GROOT ET AL., ENDOCRINE REV., vol. 27, 2006, pages 535 - 60 |
DING K ET AL., J BIOL CHEM, vol. 289, 6 June 2014 (2014-06-06), pages 16057 - 71 |
DRILON, A.E. ET AL., J CLIN ONCOL, vol. 33, 2015, pages 8007 |
ESSEGHIR, S. ET AL., CANCER RES., vol. 67, 2007, pages 11732 - 11741 |
EXPERT OPIN. THER. PAT., vol. 19, no. 3, 2009, pages 305 - 319 |
EXPERT. OPIN. THER. PAT., vol. 24, no. 7, 2014, pages 731 - 744 |
FLAVIN, R. ET AL., UROL. ONCOL., vol. 30, 2012, pages 900 - 905 |
FUGAZZOLA ET AL., ONCOGENE, vol. 13, no. 5, 1996, pages 1093 - 7 |
GAO L ET AL., PANCREAS, vol. 44, January 2015 (2015-01-01), pages 134 - 143 |
GATTEI, V. ET AL., ANN. HEMATOL, vol. 77, 1998, pages 207 - 210 |
GATTEI, V. ET AL., BLOOD, vol. 89, 1997, pages 2925 - 2937 |
GATTELLI, A., EMBO MOL. MED., vol. 5, 2013, pages 1335 - 1350 |
GIL ET AL., J. NATL. CANCER INST., vol. 102, 2010, pages 107 - 18 |
GOZGIT ET AL., AACR ANNUAL MEETING, 2014 |
GRECO ET AL., Q. J. NUCL. MED. MOL. IMAGING, vol. 53, 2009, pages 440 - 54 |
GRIECO ET AL., CELL, vol. 60, 1990, pages 557 - 63 |
HEZAM K ET AL., REV NEUROSCI, vol. 29, 26 January 2018 (2018-01-26), pages 93 - 98 |
HOFFMAN; J.M. ET AL., GASTROENTEROLOGY, vol. 142, 2012, pages 844 - 854 |
HOFSTRA, R. M., W. ET AL., HUM. GENET., vol. 97, 1996, pages 362 - 364 |
IJAE, vol. 115, 2010, pages 117 |
INT. J. CANCER, vol. 72, 1997, pages 672 - 679 |
ITO ET AL., SURGERY, vol. 138, 2005, pages 788 - 94 |
ITO, Y ET AL., SURGERY, vol. 138, 2005, pages 788 - 794 |
IWAHASHI ET AL., CANCER, vol. 94, 2002, pages 167 - 74 |
J. CARCINOG., vol. 12, 2013, pages 22 |
J. KOOISTRA; G. K. KANEV; O. P. J. VAN LINDEN; R. LEURS; I. J. P. DE ESCH; C. DE GRAAF: "KLIFS: A structural kinase-ligand interaction database", NUCLEIC ACIDS RES., vol. 44, no. D1, 2016, pages D365 - D371 |
J. MED. CHEM., vol. 51, no. 15, 2008, pages 4672 - 4684 |
J. MED.CHEM., vol. 55, no. 10, 2012, pages 4872 - 4876 |
J. NEUROCHEM., vol. 72, 1999, pages 919 - 924 |
JOURNAL OF THORACIC ONCOLOGY, vol. 7, no. 12, 2012, pages 1872 - 1876 |
JPN. J. CANCER RES., vol. 86, 1995, pages 1127 - 30 |
JU ET AL., GENOME RES., vol. 22, 2012, pages 436 - 45 |
KARACHIALIOU ET AL.: "Real-time liquid biopsies become a reality in cancer treatment", ANN. TRANSL. MED., vol. 3, no. 3, 2016, pages 36 |
KATO ET AL., CLIN. CANCER RES., vol. 23, 2017, pages 1988 - 1997 |
KESZTHELYI, D., EUR. J. PAIN, vol. 16, 2012, pages 1444 - 1454 |
KIM ET AL., ONCOLMMUNOLOGY, vol. 5, no. 2, 2016, pages e1069940 |
KOHLMANN, A. ET AL., J. CLIN. ONCOL., vol. 28, 2010, pages 2858 - 2865 |
KOHNO ET AL., NATURE MED., vol. 18, 2012, pages 375 - 7 |
KUBLER ET AL., J. IMMUNOTHER CANCER, vol. 3, 2015, pages 26 |
LIPSON ET AL., NATUREMED., vol. 18, 2012, pages 382 - 4 |
LOPEZ-DELISLE ET AL., ONCOGENE, 2018 |
LOUIS, D.N. ET AL., ACTA NEUROPATHOL, vol. 131, no. 6, June 2016 (2016-06-01), pages 803 - 820 |
LUO, Y. ET AL., ONCOGENE, vol. 32, 2013, pages 2037 - 2047 |
MOL. CANCER THER., vol. 6, 2007, pages 3158 |
MOL. CANCER THER., vol. 8, 2009, pages 1818 - 1827 |
MOL. CELL BIOCHEM., vol. 339, no. 1-2, 2010, pages 201 - 213 |
MORANDI, A. ET AL., CANCER RES., vol. 73, 2013, pages 3783 - 3795 |
MULLIGAN, L. M. ET AL., GENES CHROMOSOMES CANCER, vol. 21, 1998, pages 326 - 332 |
MULLIGAN, L. M., NATURE REVIEWS CANCER, vol. 14, 2014, pages 173 - 186 |
NARITA, N. ET AL., ONCOGENE, vol. 28, 2009, pages 3058 - 3068 |
NATURE REVIEWS CANCER, vol. 14, 2014, pages 173 - 186 |
NELSON-TAYLOR ET AL., MOL. CANCER THER., vol. 16, 2017, pages 1623 - 1633 |
O. P. J. VAN LINDEN; A. J. KOOISTRA; R. LEURS; I. J. P. DE ESCH; C. DE GRAAF: "KLIFS: A knowledge-based structural database to navigate kinase-ligand interaction space", J. MED. CHEM., vol. 57, no. 2, 2014, pages 249 - 277 |
OTT ET AL., NATURE, vol. 547, 2017, pages 217 - 221 |
PETERSEN, S.; BOGENMANN, E., ONCOGENE, vol. 23, 2004, pages 213 - 225 |
PLAZA-MENACHO ET AL., ONCOGENE, vol. 29, 2010, pages 4648 - 57 |
PLAZA-MENACHO, I. ET AL., ONCOGENE, vol. 29, 2010, pages 4648 - 4657 |
PLOS ONE, vol. 9, 2014, pages e95628 |
PLOSKER, DRUGS, vol. 71, no. 1, 2011, pages 101 - 108 |
POSTOW, M.A. ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 33, 2015, pages 1974 - 1982 |
Q. HUANG ET AL.: "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma", MOL. CANCER THER., vol. 18, 2016, pages 2521 - 2529 |
RAUSCH ET AL., HUMAN VACCIN IMMUNOTHER, vol. 10, no. 11, 2014, pages 3146 - 52 |
ROMEI; ELISEI, FRONT. ENDOCRINOL. (LAUSANNE), vol. 3, 2012, pages 54 |
RUDOLPH AM ET AL.: "Rudolph's Pediatrics", 2002, MCGRAW-HILL |
SAHIN ET AL., NATURE, vol. 547, 2017, pages 222 - 226 |
SANTORO ET AL., ONCOGENE, vol. 12, 1996, pages 1821 - 6 |
SJOBLOM, T. ET AL., SCIENCE, 2006, pages 268 - 274 |
SONG EUN-KEE ET AL., INTERNATIONAL JOURNAL OF CANCER, vol. 136, 2015, pages 1967 - 1975 |
TAKEUCHI ET AL., NATUREMED., vol. 18, 2012, pages 378 - 81 |
TANG ET AL., MOD. PATHOL., 2017 |
TARAVIRAS, S. ET AL., DEVELOPMENT, vol. 126, 1999, pages 2785 - 2797 |
WELLS; SANTORO, CLIN. CANCER RES., vol. 15, 2009, pages 7119 - 7122 |
WOOD ET AL., SCIENCE, vol. 318, 2007, pages 1108 - 13 |
YASUYUKI KANETA ET AL.: "Abstract B173: Preclinical characterization and antitumor efficacy of DS-5010, a highly potent and selective RET inhibitor", MOL CANCER THER, vol. 17, no. 1, 1 January 2018 (2018-01-01), pages B173 |
ZENG, Q. ET AL., J. INT. MED. RES., vol. 36, 2008, pages 656 - 664 |
ZENG, Q. ET AL., J. INT. MED. RES., vol. 36, no. 4, 2008, pages 656 - 64 |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11279688B2 (en) | 2015-11-02 | 2022-03-22 | Blueprint Medicines Corporation | Inhibitors of RET |
US11872192B2 (en) | 2018-04-03 | 2024-01-16 | Blueprint Medicines Corporation | RET inhibitor for use in treating cancer having a RET alteration |
US11273160B2 (en) | 2018-04-03 | 2022-03-15 | Blueprint Medicines Corporation | RET inhibitor for use in treating cancer having a RET alteration |
WO2020033838A2 (fr) | 2018-08-10 | 2020-02-13 | Blueprint Medicines Corporation | Traitement du cancer à egfr mutant |
WO2020083332A1 (fr) * | 2018-10-24 | 2020-04-30 | 南京明德新药研发有限公司 | Dérivé de pyrimidine tenant lieu d'inhibiteur ret |
CN111285882A (zh) * | 2018-12-07 | 2020-06-16 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物、包含其的药物组合物及其制备方法和用途 |
WO2020188015A1 (fr) | 2019-03-21 | 2020-09-24 | Onxeo | Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer |
WO2020200314A1 (fr) * | 2019-04-03 | 2020-10-08 | 南京明德新药研发有限公司 | Dérivé spiro contenant de l'azote utilisé en tant qu'inhibiteur de ret |
CN113474345A (zh) * | 2019-04-03 | 2021-10-01 | 广州白云山医药集团股份有限公司白云山制药总厂 | 作为ret抑制剂的含氮螺环衍生物 |
CN113474345B (zh) * | 2019-04-03 | 2023-04-18 | 广州白云山医药集团股份有限公司白云山制药总厂 | 作为ret抑制剂的含氮螺环衍生物 |
JP2022529086A (ja) * | 2019-04-03 | 2022-06-16 | 広州白雲山医薬集団股分有限公司白雲山制薬総廠 | Ret阻害剤としての窒素含有スピロ環誘導体 |
JP7198386B2 (ja) | 2019-04-03 | 2022-12-28 | 広州白雲山医薬集団股分有限公司白雲山制薬総廠 | Ret阻害剤としての窒素含有スピロ環誘導体 |
WO2020207419A1 (fr) | 2019-04-12 | 2020-10-15 | 浙江海正药业股份有限公司 | Dérivé de pipérazine amide, son procédé de préparation et son utilisation en médecine |
CN113784963A (zh) * | 2019-05-20 | 2021-12-10 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
CN113784963B (zh) * | 2019-05-20 | 2024-02-27 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
JP2022534067A (ja) * | 2019-05-20 | 2022-07-27 | ティーワイケー メディシンズ インコーポレーテッド | Retキナーゼ阻害剤としての化合物およびその使用 |
EP3974422A4 (fr) * | 2019-05-20 | 2023-02-01 | TYK Medicines Inc. | Composé utilisé comme inhibiteur de kinase ret et son utilisation |
EP3974432A4 (fr) * | 2019-05-21 | 2023-06-28 | Voronoi Inc. | Dérivé hétéroaryle contenant de l'azote et composition pharmaceutique le comprenant en tant que principe actif pour prévenir ou traiter le cancer |
CN113853375A (zh) * | 2019-05-21 | 2021-12-28 | 株式会社沃若诺伊 | 含n杂芳基衍生物及包含其作为活性成分的用于预防或治疗癌症的药物组合物 |
CN113853375B (zh) * | 2019-05-21 | 2024-03-08 | 株式会社沃若诺伊 | 含n杂芳基衍生物及包含其作为活性成分的用于预防或治疗癌症的药物组合物 |
WO2021089791A1 (fr) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
US11963958B2 (en) | 2020-10-02 | 2024-04-23 | Rigel Pharmaceuticals, Inc. | RET inhibitor for use in treating cancer having a RET alteration |
WO2023239422A2 (fr) | 2021-10-22 | 2023-12-14 | University Of Houston System | Méthodes et compositions pour traiter une lésion inflammatoire chronique, une métaplasie, une dysplasie et des cancers des tissus épithéliaux |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11851434B2 (en) | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | |
WO2018136663A1 (fr) | Inhibiteurs de ret | |
US11603374B2 (en) | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors | |
CA3079012A1 (fr) | Formes cristallines | |
JP2020514356A (ja) | Ros1キナーゼ阻害剤としての大環状化合物 | |
US11472802B2 (en) | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors | |
US11524963B2 (en) | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors | |
EP3849986B1 (fr) | Composés hétérocycliques condensés comme inhibiteurs de kinases ret | |
US11964988B2 (en) | Fused heterocyclic compounds as RET kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18705745 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18705745 Country of ref document: EP Kind code of ref document: A1 |